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ABSTRACT 
 
Allogeneic haematopoietic stem cell transplantation (HSCT) involves the infusion of 
haematopoietic progenitor and stem cells, obtained from donor marrow or other 
sources, which engraft and under optimal circumstances repopulate and reconstitute the 
host‟s immune system. Transplantation of allogeneic haematopoietic stem cells requires 
careful matching of donor and recipient. Failure to do so may lead to delayed or 
incomplete engraftment, complications such as graft-versus-host disease (GVHD) or 
graft failure. 
 
Allogeneic HSCT is a treatment of increasing prevalence for a range of haematological 
malignancies, marrow failure states, immune deficiencies and some solid tumours. In 
Australia, major indications for allogeneic HSCT are acute myeloid leukaemia, non-
Hodgkin‟s lymphoma and acute lymphoid leukaemia (Nivison-Smith, Bradstock et al. 
2007). However, allogeneic HSCT is associated with serious and debilitating long-term 
complications which confer increased morbidity and mortality. These complications 
commonly involve the oral tissues and salivary glands potentially causing a detrimental 
impact on oral health and function. The most significant of these include the 
development of new or second malignant neoplasm‟s and oral chronic GVHD. 
 
Of the 277 patients who received allogeneic HSCT from 2003 to 2008, 132 transplant 
recipients were still living and 88 participated in this study. Data analysis has shown a 
striking prevalence of oral manifestations of chronic GVHD with over 50% of subjects 
showing objective evidence of long-term complications from transplantation. Common 
presentations included salivary hypofunction, mucosal changes consistent with chronic 
GVHD, reduction in oral aperture and the presence of candidosis. 
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Chapter 1: LITERATURE REVIEW 
Allogeneic Haematopoietic Stem Cell Transplantation 
1.1 Definition 
Stem cell transplantation involves eliminating the patient‟s (host) haematopoietic and 
immune system via chemotherapy and/or radiotherapy, termed conditioning therapy, 
and replacing it with stem cells derived from another individual (the donor) or with 
previously harvested stem cells from the patient themselves. Human stem-cell 
transplantation (HSCT) may be syngeneic, where stem cells are obtained from an 
identical twin, allogeneic, when donor stem cells are utilised or autologous, where the 
patient‟s own stem cells are used. Allogeneic HSCT involves the intravenous infusion 
of haematopoietic progenitor and stem cells, obtained from donor marrow or other 
sources, which then engraft and under optimal circumstances repopulate and 
reconstitute the host‟s immune system. Transplantation of allogeneic haematopoietic 
stem cells requires careful matching of donor and recipient. Failure to do so is 
associated with delayed or incomplete engraftment and with graft-versus-host disease 
(GVHD) (Hoffman, Benz et al. 2009). 
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1.2 Principles of Haematopoietic Allogeneic Stem Cell Transplantation 
1.2.1 Selection of a donor 
Successful allogeneic HSCT relies on molecular typing to facilitate precise human 
leukocyte antigen (HLA) matching between donor and host. If incompatible with the 
host, HLA antigens elicit both humoral and cell-mediated host responses which may 
progress to rejection and destruction of the graft.  
 
The major histocompatability complex (MHC) genes are a set of highly pleomorphic 
glycoproteins which are found on specific cell surfaces in mammals, they are intimately 
involved in antigen recognition and allow the immune system to distinguish self from 
non-self. MHC enable the presentation of peptides, derived from antigens, onto the cell 
surface and thus to the immune system. The human equivalent of MHC are the HLA 
which are located on the short arm of chromosome 6 and are divided into class I and 
class II antigens. The class I antigens (HLA-A, -B, -C) are expressed on all nucleated 
cells in the body. Class I HLA bind and present peptides derived from degraded 
intracellular proteins to CD8
+
 cells and thus allow the immune system to recognise self 
from non-self. The class II antigens (HLA-DR, -DP, -DQ) are located on antigen 
presenting cells and bind peptides derived from degraded extracellular proteins and thus 
help to regulate the immune response by allowing the recognition of foreign antigens.  
 
The MHC genes are inherited as haplotypes, that is, they are inherited as a unit. 
Molecular typing is performed to allow for precise HLA matching between prospective 
donors and the recipient however considerable genetic disparity may still exist via the 
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minor histocompatability antigens (mHags). Minor histocompatability antigens may 
reflect polymorphisms of normal cellular proteins that are not shared between donor 
and recipient (Cutler, Antin et al. 2006). Identification of these mHags by donor T-cells 
leads to the generation of an immune response which may result in GVHD and also the 
graft-versus leukaemic effect (GVL) (Copelan 2006). In contrast, recognition of the 
foreign donor cells by residual host T-cells may lead to graft rejection. 
 
In the process of donor selection, donors are broadly categorised as HLA identical or 
non-identical donors (Table 1.2.1). For allogeneic HSCT a genotypically HLA-identical 
sibling is the ideal donor, namely, a sibling who has inherited the same paternal and 
maternal MHC genes. Donors which are a 2 haploid match are obtainable in 25% to 
30% of patients who have living siblings (Hoffman, Benz et al. 2009). Specifically, the 
donor and recipient are matched for the amino acid sequence (allele) encoded by all 
HLA loci. It may also be possible to identify individuals within families (e.g. a parent, 
uncle, aunt etc) who share one1 haplotype. These donors have one identical haplotype 
and are phenotypically matched for the non-shared haplotype. Molecular techniques, 
typically polymerase chain reaction, allow the definition of the unique sequence of 
variants (alleles) which encode each HLA molecule. 
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Approximately 70% to 75% of patients, who could benefit from HSCT, lack a suitably 
matched related donor (Hoffman, Benz et al. 2009). This has lead to the development of 
numerous donor registries. Currently there are an estimated ten million volunteer 
donors. For HSCT, HLA-A, HLA-B, and HLA-DR are routinely evaluated (Petersdorf, 
Anasetti et al. 1998). DNA-based methods have become established as the gold 
standard for HLA testing (Hoffman, Benz et al. 2009). Where possible, unrelated 
donors are completely phenotypically matched for critical HLA class I and II antigens. 
However, even in closely matched related donors mismatched mHags, encoded outside 
the MHC in the recipient, may be recognised as antigens by the donor T cells resulting 
in an immune response which may lead to graft rejection or GVHD. When HLA 
disparity cannot be avoided, selection of a donor with the least HLA mismatches may 
allow the avenue of transplantation for a wider group of patients. Clearly, the use of an 
as closely matched donor as possible increases the chances of successful engraftment 
and reduces the risk of GVHD (Flomenberg, Baxter-Lowe et al. 2004). Several studies 
Table 1.2.1: Donor types in Allogeneic HSCT (Hoffman Basic principles and practice, 5th ed) 
Allogeneic HSCT Donor types Histocompatability 
barrier 
  Minor Major 
 HLA genotypically/ phenotypically 
identical donor 
+ - 
 Related + -/+ 
 Unrelated +++ -/+ 
HLA non-identical donor   
 Related + ++ 
 Unrelated +++ ++ 
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have shown that approximately 40% of recipients of HLA identical grafts develop acute 
GVHD however this increases to between 60%-80% in recipients of unrelated or one-
antigen HLA mismatched grafts (Anasetti, Amos et al. 1989; Flomenberg, Baxter-Lowe 
et al. 2004). 
 
Criteria independent of HLA are considered in donor selection when greater than one 
HLA-identical match is available for a given patient. For example, a younger donor age 
is significantly associated with an improved clinical outcome (Confer and Miller 2007). 
With each decade of life in a donor, the risk of acute and chronic GVHD increases by 
10% (Hoffman, Benz et al. 2009). In contrast, donor ABO blood type has not been 
shown to influence the risk of GVHD or mortality (Hoffman, Benz et al. 2009).  
 
Identified matched donors also undergo a screening medical history, physical 
examination and laboratory testing specifically for transmissible diseases: hepatitis B, C 
and A, human immunodeficiency virus, cytomegalovirus (CMV) and treponema 
pallidum. 
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1.2.2 Stem Cell Source 
Mature haematopoietic cells are produced continuously by less-differentiated precursor 
cells which are ultimately, descendants from the haematopoietic stem cells. All stem 
cells have the capability to produce both mature differentiated cells and daughter cells. 
Daughter cells are self renewing and retain stem-cell properties and thus allow 
continual propagation of the haematopoietic cell cascade. Currently, for allogeneic 
HSCT, stem cells are harvested from three sites: the bone marrow, peripheral blood and 
umbilical cord blood. Classically, stem cells are collected from the donor bone marrow, 
most commonly from the posterior iliac crest and typically during a general anaesthetic 
or regional anaesthesia. Multiple aspirations are required with collection of 
approximately 5 mL of marrow from each puncture site. Bone marrow was the 
originally preferred source due to the ease and reliability of collecting adequate 
numbers of cells. In 1994, the first allogeneic transplant utilising peripheral blood-
derived haematopoietic stem cells was performed in Australia (Nivison-Smith, 
Bradstock et al. 2005). Marrow stem cells continuously detached and enter the 
circulation making peripheral blood a convenient source of haematopoietic stem cells. 
The proportion of HSCT harvested from bone marrow have declined in recent years 
with peripheral blood being the currently preferred stem cell source in Australia and 
New Zealand, with 71% of allogeneic HSCT utilising this source in 2004 (Nivison-
Smith, Bradstock et al. 2007). 
 
Peripheral blood stem cells are collected using a cell-separator which is connected to 
the donor usually via peripheral cannulae. Mononuclear cells are collected by 
centrifugation whilst the erythrocytes are returned to the patient. The peripheral blood 
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contains significantly fewer stem cells relative to the bone marrow therefore pre-
treatment of the marrow is frequently required. The number of peripheral blood stem 
cells is estimated  by  the cell surface molecule CD34+, which is used as a marker 
(Copelan 2006). The proportion of CD34+ cells in blood can be raised by the use of 
growth factors, such as granulocyte-macrophage colony-stimulating factor (GM-CSF) 
or granulocyte colony-stimulating factor (G-CSF). Growth factors may be given to 
donors for 4-6 days (typically 10μg/kg/day) prior to collection to aid in stem cell 
mobilisation (Hoffbrand, Moss et al. 2006). G-CSF, causes the proliferation of 
neutrophils and the release of proteases. These proteases degrade the proteins which 
anchor the stem cells to the marrow stroma and, in combination with other factors, free 
the cells to enter the circulation (Levesque, Liu et al. 2004). Peripheral blood stem cell 
transplantation (PBSCT) is associated with significantly faster engraftment times 
relative to marrow in allogeneic HSCT (Nivison-Smith, Bradstock et al. 2007). 
However, due to a raised yield of T cells some studies have demonstrated an increased 
risk for the development of chronic GVHD in these recipients (Schaffer 2006). 
 
The most recent advance in stem cell collection has been the introduction of umbilical 
cord blood (UCB) transplants, specifically for patients undergoing unrelated donor 
transplantation who lack an appropriate related or unrelated volunteer donor. Umbilical 
cord blood is collected from the placental vein after delivery of the infant and 
transection of the cord. Foetal blood contains a relatively large proportion of 
haematopoietic stem cells and UCB has been used successfully as a source of stem 
cells. The most significant hindrance in the utilisation of this source relates to the 
limited number of stem cells which can be collected from each sample. Umbilical cord 
blood transplantation has been linked to delayed haematopoietic recovery and therefore 
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a greater risk of posttransplant infections in combination with a higher incidence of 
graft failure (Schaffer 2006). Nevertheless a recent increase in the number of allogeneic 
HSCT using cord blood in Australia and New Zealand has been recorded with a rise 
from 12 such transplants in 2002 to 33 in 2004 (Nivison-Smith, Bradstock et al. 2007).  
 
1.2.3 Processing 
Manipulation of the harvested stem cell population, intended for haematopoietic stem 
cell rescue, aims to remove those components which are unwanted or may cause 
adverse effects, or to positively select a desired population such as the CD34+ cells 
(Hoffman, Benz et al. 2009). Routine minimal manipulation includes the removal of 
erythrocytes or plasma to overcome ABO blood group incompatibility between the 
recipient and donor. Elimination is achieved via centrifugation of the graft. Typically a 
maximal limit of incompatible erythrocytes can be tolerated by the recipient; exceeding 
this limit places the recipient at risk of hemolysis and transfusion reaction.  
 
Another critical cell routinely manipulated in the haematopoietic stem cell graft is the T 
cell. Transplanted T cells have the potential to cause severe and at times lethal GVHD. 
Conversely T cells are also known to exert the potentially beneficial GVL effect. Many 
studies have attempted to identify the particular subpopulations involved in these two 
opposing processes. This would allow manipulation of allogeneic HSCT grafts to 
remove GVHD-producing T cells while sparing those subpopulations which initiate the 
desired GVL response (Hoffman, Benz et al. 2009). At this time there is no general 
consensus as to which populations should be targeted.  
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Several methods have been established to manipulate the graft T cell population prior to 
infusion. The technique currently favoured utilises specific monoclonal antibodies 
directed toward the antigens which identify unique T-lymphocyte subpopulations. The 
target population is then eliminated with superior efficiency using immunomagnetic 
separation. Various antigens have been identified including CD3 and CD2 for pan–T-
cell depletions or CD4 and CD8 for the elimination of helper and suppressor T cells 
(Miller, Soignier et al. 2005). 
 
Manipulation techniques mentioned to this point are negative selection techniques by 
nature as they eliminate identified populations, typically T cells or tumour cells, from 
the graft population. Conversely, identification of an antigen localised on the 
pluripotent cells essential for transplantation, namely the CD34 antigen, allowed 
development of manipulation techniques which cause enrichment of chosen cell 
populations. However, a concern raised about positive selection techniques is the fact 
that this process leads to the concomitant elimination of the non-target cell populations. 
These subpopulations may be of potential benefit to the host, for example, the T cell 
subpopulations involved in the GVL effect or those which facilitate engraftment 
(Hoffman, Benz et al. 2009). The future success of positive selection techniques relies 
on the identification of these subpopulations so that they may be recovered from the 
selected cell population and reintroduced to the final desirable graft cell population 
(Hoffman, Benz et al. 2009). 
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1.2.4 Conditioning 
Prior to the infusion of the harvested haematopoietic stem cells a combination of anti-
neoplastic or immunosuppressive agents are utilised (either chemical or physical 
agents), the aim being; to eradicate the host‟s immune and haematopoietic system so as 
to allow engraftment along with destruction of any residual malignancy. This 
preparative process, prescribed for the host, is known as conditioning. Conditioning 
regimes are classified as myeloablative or non-myeloablative. The object of 
myeloablative preparation is both to eradicate malignant cells and to induce 
immunosuppression to allow engraftment (Copelan 2006). A non-myeloablative 
regimen has been defined as a preparatory regime which should not eradicate host 
haematopoiesis and should allow haematopoietic recovery in less than 28 days without 
haematopoietic cell transplant (Champlin, Khouri et al. 2003). Non-myeloablative 
methods do not wholly eradicate host malignant cells and therefore rely on the immune-
mediated effects of the donor cells to eliminate residual disease. Lastly, a reduced 
intensity conditioning (RIC) regime follows the principles of non-myeloablative 
techniques however HSCT is still required for marrow reconstitution and rescue.  
 
Reduced intensity regimes are formulated to initiate less host tissue damage and 
inflammatory cytokine release, thus lowering the risk of transplant-related mortality 
(TRM) and, possibly, the incidence and intensity of GVHD (Wagner, Barker et al. 
2002). Unlike myeloablative treatments, these regimens are primarily 
immunosuppressive and depend on the GVL effect to eradicate malignant cells. These 
features have allowed the application of HSCT to a wider group of patients who were 
previously excluded, most commonly due to comorbidities or age (Takahashi, Iseki et 
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al. 2004). Conversely, RIC regimes have a less potent antitumour effect and thus may 
not be ideal in all cases. Allogeneic HSCT, after the provision of RIC, is most effective 
in treating slower-growing malignancies such as chronic lymphocytic leukaemia. The 
most recently published European Group for Blood and Marrow Transplantation 
(EBMT) survey showed a continued rise in RIC HSCT from 3301 cases in 2005 to 
3530 in 2006, with RIC used in 34% of all allogeneic HSCT (Gratwohl, Baldomero et 
al. 2007). 
 
Conditioning protocols include various forms of chemotherapy in combination with, or, 
in place of, total body irradiation (TBI). Specific agents used and their combinations 
vary widely amongst institutions and are influenced by the underlying disease process 
and transplant factors. As the name implies, TBI involves the delivery of radiation to 
the entire body however certain radiosensitive organs are commonly shielded, such as 
the lungs. TBI is myeloablative and immunosuppressive in nature and addresses sites 
not affected by chemotherapy (Copelan 2006). More recently, low dose TBI, in 
combination with immunosuppressive drugs, has been used as RIC regimens with lower 
toxicity.  
 
The total dose of TBI used in HSCT typically ranges from 8-15 Gray (Gy) (Thomas, 
Buckner et al. 1979) which may be administered as a single dose or divided into smaller 
doses delivered over a course of days (fractionated) through the use of high energy 
photon beams, generally delivered by linear accelerators. TBI maximises malignant cell 
destruction with minimal damage to healthy cells by exploitation of the relatively 
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limited capacity of malignant cells to undergo repair. Although TBI does decrease the 
malignant cell load, the dosages commonly utilised are not intended as a standalone 
treatment but as a preparatory procedure to establish host immunosuppression to 
prevent graft rejection and to reduce the proportion of malignant cells. 
 
Fractionated TBI (8–15 Gy in single or fractionated doses) combined with 
cyclophosphamide (commonly 60 mg/kg/day for 2 days) has been the standard 
myeloablative conditioning regimen since the 1980s (Thomas, Buckner et al. 1979).  A 
common alternative utilises busulfan (typically 4 mg/kg/day for 4 days orally or 3.2 
mg/kg/day intravenously) in place of TBI with cyclophosphamide (Hoffman, Benz et 
al. 2009).  At least 36 hours are needed following the last chemotherapeutic dose for 
drug elimination prior to the infusion of the donor stem cells (Hoffbrand, Moss et al. 
2006). Common conditioning related complications include mucositis and the 
consequent need for parenteral nutrition.  
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1.2.5 GVHD Prophylaxis 
GVHD, a condition of T cell mediated alloreactivity, is a common outcome of 
allogeneic HSCT and may lead to significant morbidity and mortality. The most 
effective technique for the prevention of GVHD is ex-vivo depletion of donor T 
lymphocytes prior to infusion. Although this technique may reduce the incidence of 
aGVHD and hence cGVHD, it also places the patient at an increased risk of graft failure 
and relapse (Ho and Soiffer 2001). 
 
Pharmacological immunosuppression is routinely prescribed following allogeneic 
HSCT with the aim to eliminate or blunt T lymphocyte recognition and proliferation 
which is responsible for the initiation of GVHD. The duration of immunosuppression 
varies between patients however several months (approximately 6 months) are 
generally required to allow the development of immune system tolerance and 
lymphohaematopoietic chimerism (Bolanos-Meade 2006). Agents which are frequently 
utilised, singularly or in combination, include methotrexate, corticosteroids, 
cyclosporine, and tacrolimus (Ruutu, Hermans et al. 1998). 
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1.2.6 Indications for allogeneic HSCT 
Allogeneic HSCT has evolved as a curative therapy for a variety of haematological 
malignancies, marrow failure states, immune deficiencies and some solid tumours. This 
is reflected in a greater than 3-fold increase in the utilisation of this treatment modality 
in the past 15 years (Gratwahl, Baldomero et al. 2002). There are now an estimated 
50,000 to 60,000 HSCT performed each year. The EBMT reported a 20% increase in 
allogeneic HSCT from 2004 to 2005 comprising 37% of all HSCT in 2005 (Gratwohl, 
Baldomero et al. 2007). 
 
In Australia, the major indications for autologous HSCT in 2004 were non-Hodgkin‟s 
lymphoma (NHL) (37%) and multiple myeloma (38%).  Whereas acute myelogenous 
leukaemia (AML), NHL, and acute lymphoblastic leukaemia (ALL) were the most 
common  indications for allogeneic HSCT (Nivison-Smith, Bradstock et al. 2007). 
Multiple myeloma was also a significant indicator for allogeneic HSCT when a related 
donor was available. These indications are consistent with the reported indications for 
allogeneic HSCT in European centres (Table 1.2.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 
 
Table 1.2.6: Allograft indications by ABMRR and EMBT (Nivison-Smith, Bradstock et al. 2007) 
 Indications as a proportion of total allo-grafts 
Indication for HSCT ABMTRR* EBMT0 
Acute myelogenous leukaemia 43% 32% 
Acute lymphocytic leukaemia 19% 19% 
Chronic myeloid leukaemia 8% 11% 
Non-Hodgkin‟s lymphoma 9% 7% 
*Australasian Bone Marrow Transplant Recipient Registry (ABMRR) 
0
 European Group for Blood 
and Marrow Transplantation (EBMT) 
 
There has been a steady rise in HSCT in Australia and New Zealand with an increase of  
7% per annum since 2001 (Nivison-Smith, Bradstock et al. 2007). Influencing factors 
include the greater proportion of older patients undergoing transplantation using 
reduced intensity conditioning regimes. The use of allogeneic HSCT for chronic 
myeloid leukaemia (CML) dropped sharply since 2001 and has been relatively low 
since that time (Nivison-Smith, Bradstock et al. 2007). This is a direct result of the 
implementation of imatinib mesylate therapy (Glivec™) for the majority of newly 
diagnosed patients (Goldman 2002). 
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1.3 Early complications of allogeneic transplant 
1.3.1 Mucositis  
Mucositis, associated with HSCT, is characterised by widespread ulceration of the 
moveable, non-keratinised mucosae of the oral cavity most commonly involving the 
buccal mucosa and the ventrolateral tongue (Scully, Sonis et al. 2006). Oesophageal 
and gastrointestinal systems are also affected. It is a common acute toxicity associated 
with both intense chemotherapy reserved for haematological malignancies as well as 
head and neck radiation, both being integral components of HSCT. Oropharyngeal 
mucositis may result in severe discomfort and is the most common symptom and 
distressing complication of HSCT (Bellm, Epstein et al. 2000). Furthermore, concurrent 
therapy related immunosuppression, specifically neutropoenia, places patients at risk of 
bacteraemia, septicaemia and fungaemia (Ruescher, Sodeifi et al. 1998). Clinically, 
mucositis first presents as generalised erythema approximately 4-5 days following the 
initiation of chemotherapy or following a cumulative radiation dose of 10Gy to the head 
and neck region. At 7-10 days following chemotherapy frank ulceration occurs, 
associated with significant pain and impaired function. Mucositis commonly extends to 
involve the oesophageal and gastrointestinal mucosa. Opioid analgesics are often 
essential at this stage and total parenteral nutrition may be required.  
 
At a cumulative dose of 30Gy ulceration develops in radiation associated mucositis. 
Unlike chemotherapy, radiation leads to ulceration over any radiation-exposed area. 
TBI is the most common application of radiation in the HSCT setting. Due to the low 
radiation dosages utilised in allogeneic HSCT, mucositis is more commonly associated 
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with intensive chemotherapy in this setting. Chemotherapy induced mucositis may 
persist for approximately 1 week and generally resolves within 3 weeks after the 
initiation of chemotherapy (Scully, Sonis et al. 2006). Mucositis is seen in 75-99% of 
patients receiving myeloablative conditioning regimes for HSCT particularly those 
which also involve TBI (Donnelly, Muus et al. 1992). Conditioning regimes which are 
at high risk for mucositis include high-dose melphalan, busulphan-cyclophosphamide 
and cyclophosphamide-TBI (Wardley, Jayson et al. 2000). Recent literature has shown 
reduced severity and prevalence of mucositis with RIC where severe mucositis 
developed in 32% of patients treated with myeloablative regimens and only 7% in 
patients who received RIC (Vela-Ojeda, Garcia-Ruiz et al. 2004). 
 
Numerous interventions have been developed for the prevention or management of oral 
mucositis. A recent Cochrane review concluded benefit from ice chips and GM-CSF 
with only minimal benefit from amifostine and povidone (Clarkson 2003). Cryotherapy, 
with ice chips, causes mucosal cooling and constriction of blood vessels and is thought 
to reduce the exposure of the oral tissues to the causative chemotherapy agent (Scully, 
Sonis et al. 2006). This method has been shown to be useful for agents with a short half 
life. Ice chips, used 5 minutes prior to 5-FU bolus and continued 30 minutes after, were 
found to reduce mucositis by 50% (Loprinzi, Ghosh et al. 1997). Palifermin 
(Kepivance), a recombinant human keratinocytes growth factor, is the most recent drug 
designed to prevent mucositis. Benefits were seen when given for 3 days prior to 
conditioning (Scully, Sonis et al. 2006). 
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1.3.2 Infections  
Transplant related infections are another common complication seen in the early and 
late phase post transplant. Two main mechanisms have been identified in patients at 
increased risk for infection.  Firstly, the risk of infection is elevated when non-specific 
defences are compromised, as seen following intensive conditioning schedules where 
the integrity of surface barriers are hindered. Secondly, HSCT, by nature, causes 
deficiencies in both the humoral and cellular arms of the immune system rendering the 
patient at severe risk of infection. Recovery of granulocytes and natural killer cells is 
seen about 2 weeks following myeloablative conditioning whereas T and B cell 
function may be suppressed for prolonged periods. So, conditioning, 
immunosuppression and neutropenia, in isolation or in combination, place the patient at 
risk for early infection. RIC regimens are associated with a reduced rate of early 
infections (Copelan 2006).  
 
Bacterial infections most commonly arise from the patient‟s own commensal flora. In 
the presence of neutropenia local infections can rapidly cause septicaemia. Typically, 
gram positive skin organisms such as Staphylococcus and Streptococcus colonise 
central venous lines, whereas Gram-negative gut bacteria (Pseudomonas aeruginosa, 
Escherichia coli) may lead to septicaemia (Hoffbrand, Moss et al. 2006). Oral mucositis 
is acknowledged to be the principal risk factor for bacteramia due to viridians 
streptococci and coagulase-negative staphylococci (Epstein, Raber-Drulacher et al. 
2009). Chronic infections associated with the dentition may also represent a critical 
source of systemic infection during myelosuppression. Periodontal infections have been 
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specifically highlighted as a significant cause of systemic infection in neutropenic 
patients (Raber-Drulacher, Epstein et al. 2002) however this is not universally accepted. 
 
Viral reactivation of latent herpes viruses are a common and serious complications in 
immunosuppression associated with HSCT. Reactivation of previously acquired latent 
herpes simplex, varicella zoster, CMV and Epstein-Barr virus are commonly encounted 
in the immediate post-transplant phase. Reactivation of CMV is a particularly serious 
complication which has become significantly less common due to superior detection of 
subclinical infection, donor screening and advances in anti-viral therapies and 
prophylaxis. CMV reactivation places the patient at risk of a potentially fatal interstitial 
pneumonitis as well as hepatitis. CMV pneumonitis was once fatal to 15% of allogeneic 
HSCT recipients (Meyers, Flournoy et al. 1982). 
 
Fungal infections are a significant cause of morbidity and mortality following HSCT. 
The two  most common subtypes are yeasts, such as the Candida species, and moulds, 
of which Aspergillus is most common (Hoffbrand, Moss et al. 2006). Prophylaxis for 
bacterial, fungal and viral infections involves a combination of agents which vary 
between transplant units. For example, in our unit prophylaxis typically consists of 
Bactrim DS™ (sulfamethoxazole 800mg, trimethoprim 160 mg), penicillin V (250mg) 
and Valtrex™ (valaciclovir). 
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1.3.3 Acute graft-versus-host disease 
1.3.3.1 Classification 
Acute graft-versus-host disease (aGVHD) occurs following allogeneic HSCT and arises 
due to the reaction of donor immune cells against host tissues. Traditionally, clinical 
GVHD occurring prior to 100 days after HSCT was called aGVHD (Sullivan, Agura et 
al. 1991). The significant advances in HSCT practice have lead to profound alterations 
in the natural history and clinical picture of both acute and chronic GVHD. For 
example, in patients receiving RIC aGVHD may present more than 3 months following 
transplantation due to the extended period prior to engraftment (Mielcarek, Martin et al. 
2003). These changes have lead to a recent National Institutes of Health (NIH) 
consensus document on the classification of GVHD which recognises the unique 
clinical and pathophysiological features of acute versus chronic GVHD, removing the 
temporal basis of classification (Toubai, Sun et al. 2008).  
 
The current consensus classification system focuses on clinical manifestations, not the 
time to symptomatic onset, as determining whether the clinical picture is considered 
acute or chronic GVHD (Filipovich, Weisdorf et al. 2005). Specifically, the updated 
NIH classification system specifies that in the absence of clinical or histological 
features suggestive of cGVHD, the persistence, recurrence of new onset of 
manifestations characteristic of aGVHD should be categorised as such, regardless of 
time since transplantation (Schaffer 2006) (Table 1.3.3.1). This will be discussed in 
greater detail at a later stage. 
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Table 1.3.3.1: NIH classification system of GVHD (Filipovich, Weisdorf et al. 2005) 
Category 
Onset of symptoms 
after HSCT 
Presence of aGVHD 
features 
Presence of cGVHD 
features 
Acute GVHD    
Classic  ≤100 days Yes No 
Persistent, recurrent 
or late-onset 
> 100 days Yes No 
Chronic GVHD    
Overlap syndrome No time limit Yes Yes 
Classic No time limit No Yes 
 
 
1.3.3.2 Clinical presentation and staging 
Acute GVHD is characterised by cellular apoptosis and necrosis affecting the skin, liver 
and gastrointestinal tract. Clinically, this may present as a maculopapular rash with 
tenderness and pruritis. The palmar and plantar surfaces are often initially involved 
which may become confluent with blister formation (Figure 1.3.3.2). The onset of 
aGVHD usually correlates with donor engraftment. Gastronintesintal involvement 
manifests as diarrhoea, cramping, nausea and/or vomiting. Hyperbilirubinemia, 
evidenced by jaundice, is a hallmark of liver involvement (Jacobsohn and Vogelsang 
2007).  
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Figure 1.3.3.2: Acute GVHD. (A) Generalised eruption (B) Maculopapular rash on palm (Schaffer 2006) 
The current staging system for aGVHD (Glucksberg 1994) subdivides patients into one 
of four grades (I-IV) based on the number and extent of organ involvement (Table 
1.3.3.2).  
Table 1.3.3.2: Staging system for aGVHD (Jacobsohn and Vogelsang 2007) 
Stage Skin (BSA) Liver (bilirubin) Gut (stool output/day) 
0 No GVHD rash < 2 mg/dl 
< 500 ml/day or persistent 
nausea. 
1 Maculopapular rash < 25%  BSA 2–3 mg/dl 500–999 ml/day 
2 
Maculopapular rash 25 – 50% 
BSA  3.1–6 mg/dl 1000–1500 ml/day 
3 
Maculopapular rash >50% 
BSA  6.1–15 mg/dl Adult: >1500 ml/day 
4 
Generalized erythroderma plus 
bullous formation >15 mg/dl 
Severe abdominal pain with 
or without ileus 
Grade     
I Stage 1–2 None None 
II Stage 3 or Stage 1 or Stage 1 
III - Stage 2-3 or Stage 2-4 
IV Stage 4 or Stage 4 - 
BSA- Body surface area 
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1.3.3.3 Pathophysiology 
The pathophysiology of aGVHD was described by Ferrara and colleagues as a three-
phase process (Ferrara, Levy et al. 1999). The initial step involves damage to the host 
tissues with inflammation, from the preparative chemotherapy and/or radiotherapy 
regimen. Donor T cells are activated by the host antigens expressed by the damaged 
tissues. In the second phase, the activation phase, both recipient and donor antigen-
presenting cells (APCs), in combination with inflammatory cytokines, trigger the 
activation of donor-derived T cells, which then expand and differentiate into effector 
cells (Ferrara, Cooke et al. 2003). As mentioned previously, donor and recipient are 
usually matched at the HLA major histocompatibility loci, however, mismatches may 
arise at mHags loci. Minor histocompatability antigens may play a role in allowing graft 
and host to recognise each other as foreign. These discrepancies may lead to activation 
of immunologically competent donor T cells which respond to the phenotypically 
disparate host antigens, derived from these polymorphic mHags, presented on antigen 
presenting cells (Toubai, Sun et al. 2008). T-cell activation pathways lead to 
transcription of genes for cytokines. In the effector phase, these activated T cells and 
cytokines mediate cytotoxicity against the target host cells. 
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1.3.3.4 Incidence and Risk Factors 
The incidence of grade II-IV aGVHD is reported as 35%-50% (Jacobsohn and 
Vogelsang 2007). The chief risk factor for aGVHD is HLA disparity. With unrelated 
donor transplants, the greater the degree of HLA mismatch, the higher the likelihood of 
developing aGVHD and the worse the overall outcome (Beatty, Clift et al. 1985). 
Furthermore, the risk of GVHD has been associated with the conditioning regimen 
used. Regimens which cause extensive injury to epithelial and endothelial surfaces (Hill 
and Ferrara 2000) due to the resulting increase in permeability of epithelial barriers, 
leakage of microbial products such as lipopolysaccharide and the release of 
inflammatory cytokines (Imanguli, Alevizos et al. 2008) are especially implicated. This 
includes higher doses of irradiation and myeloablative regimens. Conversely, RIC was 
initially predicted to lead to less severe GVHD due to reduced mucosal toxicity and 
consequent initiation of proinflammatory cytokines. As yet, no conclusive evidence 
supports this hypothesis. This feature is thought to be a product of the increasing age of 
patients treated under RIC regimens (Epstein, Raber-Drulacher et al. 2009).  
 
Donor stem cell source has also been identified as an important factor in the 
development of  aGVHD with recipients of mismatched unrelated UCB transplant (4/6 
or 5/6 HLA group match) having a similar risk of aGVHD as sibling HSCT (Jacobsohn, 
Hewlett et al. 2004). This has been attributed to the immunological naiveté of the UCB 
stem cells which offers some tolerance to greater degrees of mismatch. Other known 
risk factors for aGVHD include; unrelated donors, HLA mismatched donor, older age 
of donor, multiparous female donor and older age of the recipient (Jacobsohn and 
Vogelsang 2007).  
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1.3.3.5 Prophylaxis and Management 
The currently favoured schedules for the prophylaxis of aGVHD are based on a 
combination of cyclosporine (alternatively tacrolimus) with a short course of 
methotrexate. This regimen has been shown to consistently result in a desirable 
inducement of GVHD and consequent beneficial graft-versus-tumour effect (Jacobsohn 
and Vogelsang 2007). Once GVHD occurs, most centers manage aGVHD by 
continuing prophylactic immunosuppression and adding methylprednisolone at 2 or 
2.5mg/kg/day (Ruutu, Niederwieser et al. 1997). Approximately 40%-50% of patients 
will have a  response to glucocorticosteroid therapy (Jacobsohn and Vogelsang 2007). 
Salvage therapy is implemented for steroid refractory cases. There is currently no 
standard approach for the management of steroid refractory aGVHD; some options 
include anti-thymocyte globulin, extracorporeal photopheresis and monoclonal 
antibodies, such as daclizumab and infliximab.  
 
The prognosis of patients with aGVHD correlates with the initial clinical staging. 
Patients with Grade III aGVHD have a 30% probability of long term survival whereas 
those with Grade IV a GVHD show less than 5% survival (Cahn, Klein et al. 2005). 
Importantly, over half of the patients with aGVHD, regardless of the stage, will later go 
on to develop cGVHD (Jacobsohn and Vogelsang 2007). 
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1.3.4 Taste alteration 
Alteration in taste (dysgeusia) or a reduction or loss in taste sensation (hypogeusia / 
ageusia) is commonly associated with both myeloablative and RIC preparative 
regimens. Furthermore, medications commonly utilised in GVHD prophylaxis, such as 
cyclosporine and tacrolimus, may also induce taste changes, commonly described as 
metallic, sweet, salty, sour and/or bitter (Epstein, Raber-Drulacher et al. 2009). Taste 
dysfunction may persist for days to months but typically fully recovers (Marinone, 
Rizzoni et al. 1991).  
 
The precise aetiopathogenesis of taste dysfunction in HSCT is unknown however is 
thought to be influenced by direct toxicity of cytotoxic agents to taste buds, immune-
mediated GVHD salivary damage and psychological changes, including conditioned 
food aversion (Epstein, Raber-Drulacher et al. 2009). Hyposalivation and xerostomia 
are common complications following HSCT with xerostomia being reported as the 
second most distressing symptom at discharge and at one year following HSCT 
(Larsen, Nordstom et al. 2007). Significant outcomes associated with taste derangement 
include weight loss, emesis and reduced quality of life. 
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1.4 Chronic complications of transplant 
1.4.1 Graft-versus-leukaemic effect 
In order for an allogeneic transplant to be maximally effective, malignant cells ideally 
must be subject to immunologic control. A critical therapeutic effect of HSCT in 
eliminating malignant cells is the graft-versus-leukaemic effect (GVL). The GVL effect 
is attributed to the immunological attack of the host tissue and, therefore, the 
leukaemia/malignancy by the allogeneic graft (Hoffman, Benz et al. 2009). This effect 
was first recognised over 50 years ago in experimental models by Barnes and Loutit 
(Barnes, Corp et al. 1956). The mechanisms behind the GVL effect are poorly 
understood. The GVL effect may be achieved through the presentation of molecules on 
the cell surfaces of the residual malignant cell population which can be recognised by 
the immune response. The antigens presented may be unique tumour antigens or, more 
likely, the same antigens which are responsible for inducing and sustaining GVHD 
against the hosts normal, non-malignant cells (Cutler, Antin et al. 2006). Of note, the 
literature demonstrates a clear relationship between the development of cGVHD and the 
anticancer effect of the GVL effect. Therefore it is clear that the GVL effect is a 
beneficial outcome associated with the development of cGVHD however, this cannot be 
separated from the substantial morbidity and mortality associated with cGVHD, if 
uncontrolled or severe. 
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1.4.2 Second malignancies 
The development of new or second malignant neoplasms and lymphoproliferative 
disorders following HSCT have long been recognised as a rare but significant 
complication for long-term survivors (Demarosi, Lodi et al. 2005). Relative to the 
general population, HSCT survivors have a 13-fold higher risk for developing second 
malignancies, including leukaemias, lymphoproliferative disorders and solid tumours 
(Curtis, Rowlings et al. 1997). In the early post-transplant period, with a peak in the 
first 1 to 2 years, lymphoproliferative disorders and haematologic malignancies 
predominate as the most prevalent second malignancies. Common forms include 
leukaemia of the donor–derived cells and both Hodgkin‟s and non-Hodgkin‟s 
lymphoma.  
 
In contrast to second leukaemias and lymphoproliferative disorders, solid tumours may 
develop many years following HSCT with their incidence continuing to rise over the 
years following transplantation. The most common solid malignancy is squamous cell 
carcinoma (SCC) however melanoma, glioblastoma and sarcoma have also been 
described (Epstein, Raber-Drulacher et al. 2009). The most significant risk factors 
identified in the literature include; the duration of immunosuppressive therapy for 
cGVHD, particularly the use of azathioprine (AZA), and the severity of cGVHD. Other 
factors consistenly mentioned include the use of TBI, concurrent administration of 
cyclosporine/ AZA/ corticosteroids, young age at transplantation, and being male  
(Schubert and Correa 2008). In general, the risk of secondary malignancy is 
proportional to the survival time post HSCT (Schubert and Correa 2008). A recent 
international case control study found the median time from HSCT to solid tumour 
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diagnosis was 7.0 years (range 0.9-22.9 years) with a cumulative incidence of 1.1% at 
20 years (Curtis, Metayer et al. 2005). The biologic mechanisms involved in the higher 
incidence of post-transplant SCC have not been fully elucidated, however, it is 
postulated that extended periods of tissue destruction and repair seen in cGVHD in 
combination with prolonged periods of immunosuppression may lead to propagation of 
oncogenic viruses and may render tumour development more likely (Curtis, Metayer et 
al. 2005). 
 
Specific to the oral cavity, SCC and salivary gland malignancies (mucoepidermoid 
carcinoma) have been reported following HSCT (Curtis, Metayer et al. 2005; Demarosi, 
Lodi et al. 2005). Several authors have reported the development of solid malignancies 
at sites previously or concurrently affected with GVHD-related inflammatory processes 
(Abdelsayed, Sumner et al. 2002). Curtis et al reported that 72% of patients diagnosed 
with SCC following HSCT had cGVHD relative to 52% of patients in the control 
group. Critically, dysplastic pre-malignant lesions and frank malignancies may 
potentially be obscured by or may even resemble oral cGVHD and therefore can only 
be discriminated by biopsy (Schubert and Correa 2008). For this reason, long term 
follow-up of HSCT patients is essential so that suspicious lesions or frank malignancy 
can be detected at an early and potentially curable stage. The oral sites most frequently 
involved include the tongue, buccal mucosa, gingiva and lip in decreasing frequency 
(Abdelsayed, Sumner et al. 2002). Oral malignancies following HSCT have a tendency 
for aggressive behaviour and a tendency to recur. Median survival time following the 
diagnosis of invasive SCC of the oral cavity or the skin has been shown to be 1.7 and 
4.1 years respectively (Abdelsayed, Sumner et al. 2002). 
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1.4.3 Bisphosphonate-related osteonecrosis of the jaw 
Reduction in bone mineral density is a common long-term outcome following 
numerous treatment strategies for malignancy, including HSCT. Conditioning 
regimens, especially those comprising of irradiation, may initiate abnormalities in 
endocrine function. These effects may be exacerbated due to long-term corticosteroid 
therapy,the mainstay of cGVHD management. Of note, 15% of patients diagnosed with 
cGVHD will still be on immunosuppressive therapy as long as 7 years following 
transplantation (Stewart, Storer et al. 2004). Patients with a history of HSCT are 
therefore at risk of developing osteoporosis, fragility fractures and avascular 
osteonecrosis. Avascular osteonecrosis, death of bone, occurs as a result of impaired 
blood supply (Bamias, Kastritis et al. 2005) with the most commonly affected site being 
the femoral head. Risk factors which have been identified for avascular necrosis are the 
presence of acute and chronic GVHD, the dosage and duration of corticosteroid 
therapy, and young age with a reported 4 year cumulative incidence rate of 6.1% 
(Schulte and Beelen 2004). 
 
More recently the attention has been focused on complications associated with the 
antiresorptive medications prescribed to ameliorate osteoporosis and the related 
complications, namely, bisphosphonate-related osteonecrosis of the jaws (BRONJ). 
Clinically, BRONJ is defined as an area of exposed bone in the maxillofacial area that 
does not heal within 8 weeks after identification by a health care provider, in a patient 
who was receiving or had been exposed to a bisphosphonate and had not had radiation 
therapy to the craniofacial region (Khodls, Burr et al. 2007). Bisphosphonates are 
synthetic analogues of the naturally occurring pyrophosphate which have been used in 
medicine since the 1970s. Currently, this group of drugs is widely utilised in the 
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treatment of osteoporosis, for the complications associated with metastatic bone disease 
and management of primary osteolytic pathology of bone (multiple myeloma, Paget‟s 
disease) (Hewitt and Farah 2007). In patients receiving oral bisphosphonate therapy for 
osteoporosis, the estimated incidence of BRONJ is very low, estimated between 1 in 10 
000 and 1 in 1 000 000 patient-treatment years. In patients with malignancy, BRONJ 
has a significantly higher incidence estimated at 1-10 patients per 100 (Khodls, Burr et 
al. 2007). This is most likely associated with the higher dosages and more potent agents 
used for oncological indications combined with various comorbidities such as; 
concurrent corticosteroid therapy, a history of irradiation and general 
immunodeficiency.  
 
Bisphosphonates bind and accumulate in bone from which they are slowly released over 
time as bone is turned over. Bisphosphonates are thought to primarily affect osteoclast 
function by reducing their resorptive capacity, hindering their recruitment and causing 
apoptosis (Hewitt and Farah 2007). The more potent,  nitrogen-containing agents 
(pamidronate, zoledronate), have also been suggested to inhibit neoangiogenesis, 
capillary tube formation and vessel sprouting (Marx, Sawatari et al. 2005). In the HSCT 
setting bisphosphonate therapy is a critical component in the treatment of: cancer-
related hypercalcaemia, primary osteolytic malignancies of bone and for the prevention 
of osteoporosis in patients on long-term corticosteroid therapy. Hypercalcaemia, if 
untreated, may lead to confusion, pain and ultimately renal failure and death. Clearly, 
by ameliorating these complications, bisphosphonate therapy has considerably 
enhanced the quality of life and life span in these patients (Marx, Sawatari et al. 2005). 
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BRONJ may arise spontaneously however more commonly arises following invasive 
dental treatment such as extractions, trauma from ill-fitting dental prostheses or overt 
local trauma (Zarychanski, Elphee et al. 2006). The most common oral sites involved 
are the mandibular molar region. Associated infection and pain is not always reported.   
Wide debate exists in the literature pertaining to the appropriate management of 
BRONJ and the dental management of patients on bisphosphonate therapy. Due to the 
only recent discovery of this bisphosphonate-associated adverse effect, long term data is 
unavailable and recommendations are generally based on expert opinion. Prior to the 
commencement of bisphosphonate therapy patients should undergo thorough dental 
evaluation and optimal dental health should be attained (Novince, Ward et al. 2009). 
Regular dental reviews are essential following the commencement of antiresorptive 
therapy so that early intervention is possible and invasive procedures, therefore 
avoided. In the event of the development of BRONJ, there is general consensus that the 
cessation of bisphosphonate therapy appears unwarranted due to the systemic 
incorporation and long-term bioavailability of this group of drugs (Bagger, Tanko et al. 
2003). Management may include antimicrobial therapy when there is clinical evidence 
of infection, analgesics and gentle removal of loose bony sequestrae (Miglorati, 
Casiglia et al. 2005; Khosla, Burr et al. 2007).  
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1.4.4 Chronic graft-versus-host disease 
1.4.4.1 Definition 
HSCT may be the therapy of choice for a variety of diseases however it is associated 
with serious and debilitating complications, the most prevalent and significant being 
cGVHD. Unfortunately, despite significant advances in transplant techniques and post 
transplant immunosuppressive therapy, more than half of all allogeneic HSCT 
recipients develop GVHD, a major cause of morbidity and mortality (Schaffer 2006).  
Chronic GVHD remains the leading cause of non-malignancy related fatality, post 
allogeneic HSCT (Ferrara and Reddy 2006) accounting for approximately one-quarter 
of deaths in long term survivors of HSCT on the background of leukaemia and two-
thirds of deaths in HSCT for aplastic anaemia (Ratanatharathorn, Ayash et al. 2001). 
GVHD is one of the principal impediments for wider applications of HSCT. GVHD 
was initially described almost half a century ago, in 1960, following the first bone 
marrow transplantations in humans (Mathe, Bernard et al. 1960). Since this time there 
have been many advances in our understanding of its pathogenesis and the clinical 
presentations. 
 
Chronic GVHD is a multi-system long term complication of allogeneic HSCT which 
was traditionally classified as GVHD which persists or presents beyond the first 100 
days post transplant. The use of allogeneic human stem cells allows transplantation 
enriched with haematopoietic progenitor cells however, there is concomitant 
transplantation of mature CD4+ and CD8+ T cells. Beneficial outcomes of T cell 
transplantation include; rapid promotion of haematopoietic engraftment, quicker 
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reconstitution of T-cell immunity and the development of the beneficial, potent GVL 
effect. Unfortunately, both of these donor T-cell subsets also cause GVHD, the broad 
attack against the host tissues by donor T cells (Shlomchik 2007). cGVHD is 
characterised by immune disregulation, immunodeficiency, impaired organ function 
and decreased survival (Baird and Pavletic 2006).  
 
1.4.4.2 Incidence  
The incidence of cGVHD varies from 25% up to 80% in certain populations of 
allogeneic transplant recipients (Baird and Pavletic 2006). However, reliable incidence 
estimates are hindered by lack of standardised diagnostic guidelines. Of importance, 
cGVHD is increasing in prevalence as more patients survive transplantation and more 
transplantation procedures are performed using peripheral blood stem cell products 
(PBSCT), on older patients and with unrelated donors (Cutler, Antin et al. 2006). 
PBSCT is associated with a decreased relapse rate of haematological malignancies and 
an overall improvement in disease free status however it is also associated with a 
significant risk of extensive cGVHD. Prior diagnosis of aGVHD is the risk factor most 
consistently associated with subsequent cGVHD (Ferrara and Reddy 2006). The 
probability of developing cGVHD is approximately 49% in patients with a history of 
Grade I aGVHD and increases to 59%- 85% in patients with prior Grade II-IV aGVHD 
(Ratanatharathorn, Ayash et al. 2001). Other known risk factors include the use of 
female donors for male recipients, degree of HLA mismatch, TBI and the use of donor 
lymphocyte infusions (Pavletic S. Z, Smith L.M et al. 2005). 
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1.4.4.3 Pathophysiology 
As discussed earlier, successful transplantation relies on molecular typing to facilitate 
precise HLA matching between donor and host. If incompatible with the host, HLA 
antigens elicit both humoral and cell-mediated host responses which may progress to 
destruction of the graft. Relative to our understanding of aGVHD, the underlying 
pathophysiology of cGVHD has yet to be completely deciphered, however, 
incompatible HLA loci in combination with alloreactive T-cells are thought to drive the 
process. Recent literature has identified a role for regulatory T-cells, B-cells and 
specific cytokines in the development and persistence of cGVHD (Imanguli, Alevizos 
et al. 2008; Toubai, Sun et al. 2008).  
 
It has been established that for GVHD to eventuate the graft must contain 
immunologically competent cells, the recipient and donor must express significantly 
different tissue antigens to allow for the host tissue to be recognised as foreign and the 
recipient must be incapable of rejecting the graft (Barnes, Corp et al. 1956). The 
immunosuppression which ensues following HSCT, given for cGVHD prophylaxis, 
typically renders the recipient unable to reject the graft. Molecular typing is performed 
to allow for precise HLA matching between donor and recipient however considerable 
genetic disparity may still exist via the mHags. Critically, 1-10% of donor T cells 
recognise non-self HLAs on the host cells in transplantation leading to allogeneic 
recognition and graft rejection. Identification of these antigens by donor T-cells leads to 
the generation of an immune response which may result in GVHD. In contrast, 
recognition of the foreign donor cells by residual host T-cells may lead to graft 
rejection. 
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Clearly, a principal mechanism in the pathogenesis of cGVHD is the recognition, by 
donor T cells, of polymorphism in mHags between donor and recipient, generating an 
immune response with expansion of alloreactive T lymphocytes (Cutler, Antin et al. 
2006). However it seems likely that T-cell mediated recognition of these antigens is not 
the only pathogenetic mechanism occurring in cGVHD. It is also believed that the 
disregulated immune system cannot clearly distinguish autoantigens from alloantigens 
leading to a form of autoimmune reaction. Chronic GVHD shares several characteristics 
with systemic autoimmune conditions suggesting that there may be an element of 
humoral immunity involved in its pathogenesis.  
 
Although alloreactive T cells are thought to be the effector cells in cGVHD the exact 
role of other specific T cell subsets, various cytokines and the involvement of B cells 
remains to be discovered (Epstein, Raber-Drulacher et al. 2009). Tumour necrosis 
factor-α (TNF-α) and interferon-gamma (IFN-γ) are also thought to be associated with 
the development and modulation of cGVHD (Baird and Pavletic 2006). Increased 
transcription of these cytokines has been found to independently predict the onset of 
extensive cGVHD (Ritchie D, Seconi J et al. 2005). The contribution of B-cell activity 
and autoantibody production in cGVHD still remains unclear. Increased B-cell 
lymphocytes subsets and increased antibody levels are frequently seen in cGVHD. 
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1.4.4.4 Diagnosis and classification 
Historically cGVHD was defined as arising greater than 100 days post-HSCT either as 
a progression of aGVHD, following previous resolution of aGVHD or de novo 
(Sullivan, Weiden et al. 1981). In the past, any clinical manifestation present or arising 
after this time point was arbitrarily defined as cGVHD even if the clinical picture was 
indistinguishable from aGVHD. As mentioned earlier, significant advances in HSCT 
practice have lead to profound alterations in the understanding of the natural history and 
clinical picture of both acute and chronic GVHD. The current consensus favours 
clinical manifestations, not the time to symptomatic onset, as the determinant of 
whether the clinical picture is considered acute or chronic GVHD (Filipovich, Weisdorf 
et al. 2005).  
 
The recent NIH consensus classification of GVHD updated the diagnosis and 
classification of GVHD by recognising the unique clinical and pathophysiological 
features of acute versus chronic GVHD and removing the temporal basis of 
classification (Toubai, Sun et al. 2008). Diagnostic signs and symptoms are defined as 
those which establish the presence of cGVHD without the need for further 
investigations. Conversely, distinctive signs or symptoms refer to the manifestations 
which are not usually seen in aGVHD but are not considered sufficient to establish a 
definitive diagnosis of cGVHD. Rare or nonspecific features are classified as other 
features whereas common signs and symptoms are those which may be seen in both the 
acute and chronic spectrum. For the diagnosis of cGVHD the new diagnostic system 
requires at least one diagnostic manifestation or at least one distinctive manifestation 
with the supporting evidence via biopsy, laboratory testing or imaging (i.e. radiology). 
NIH diagnosis cGVHD shown in Table 1.4.4.4 (Filipovich, Weisdorf et al. 2005). 
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Table 1.4.4.4: Diagnosis of chronic GVHD (NIH diagnostic criteria 2005) 
The diagnosis of chronic GVHD requires the following: 
1. Distinction from acute GVHD.                                                                                                                         
2. Presence of at least 1 diagnostic clinical sign of chronic GVHD or presence of at least 1 
distinctive manifestation confirmed by pertinent biopsy or other relevant tests.                                                                   
3. Exclusion of other possible diagnoses. 
Scoring of organ manifestations requires assessment of signs, symptoms, laboratory values, and 
other results.                                                                                                                                                          
A clinical scoring system (0-3) is provided for evaluation of the involvement of individual 
organs and sites. The proposed global assessment of severity (mild, moderate, or severe) is 
derived by combining organ and site-specific scores. 
 
1.4.4.5 Global scoring 
Clinical scoring of individual organ systems is divided into a 4 point scale (0-3) with 0 
representing no involvement and 3 severe involvement. The scoring of organ systems 
allows for monitoring of disease extent and severity in individual organs over time.  
 
Global scoring of cGVHD was originally divided into limited and extensive forms, 
dependant on the degree of overall clinical disease and the histology of involved tissues 
(Shulman, Sullivan et al. 1980). Recent revisions have been made to more accurately 
reflect the overall clinical effect of cGVHD on the patient‟s functional capacity and the 
degree of overall organ involvement (Table 1.4.4.5.1). Global scoring of cGVHD is 
divided into grades of mild, moderate and severe depending on number of organs 
affected and degree of individual involvement (Table 1.4.4.5.2).   
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Table 1.4.4.5.1: Organ scoring of cGVHD (FILIPOVICH, WEISDORF ET AL. 2005) 
 1 2 3 
Skin 
 
<18% of BSA AND 
no sclerotic features 
19 to 50% BSA OR superficial 
sclerosis 
>50% BSA OR deep, 
“hidebound” sclerosis OR 
reduced mobility, 
ulceration 
Mouth Mild signs/symptoms 
not limiting oral intake 
Moderate signs/symptoms 
with partial limitation of oral intake 
Severe signs/symptoms 
with major limitation oral 
intake 
Eyes Mild dry eye 
symptoms (using 
eyedrops < 3x/d) OR  
asymptomatic but 
signs of 
keratoconjunctivitis 
sicca 
Moderate dry eye symptoms partially 
affecting ADL (using eyedrops > 
3x/d or 
punctual plugs), no visual 
impairment 
Severe dry eye symptoms 
significantly affecting 
ADL OR unable to work 
OR loss of vision 
GIT Symptoms without 
significant 
weight loss 
Symptoms with 5 to 15% 
weight loss 
 
Symptoms with >15% 
weight loss, 
requiring nutritional 
supplementation OR need 
for oesophageal dilation 
Liver Bilirubin, AP, AST, or 
ALT <2x upper 
normal limit 
Bilirubin, AP, AST, or ALT 2-5x 
upper normal limit OR 
bilirubin >3 mg/dL 
Bilirubin, AP, AST or 
ALT >5x upper normal 
limit 
Lungs Mild symptoms (SOB 
after 1 flight of steps); 
FEV1 60-79% 
Moderate symptoms (SOB after 
walking on flat ground);  
FEV1 40-59%  
Severe symptoms (SOB at 
rest or requiring O2); 
FEV1<39%  
Joints/ 
Fascia 
Mild tightness of arms 
or legs, mildly 
decreased range of 
motion 
At least 1 of following: 
o Tightness and joint contractures 
o Erythema, decreased  motion 
Mild-moderate limitation in daily 
activities 
Contractures with 
significantly 
decreased range of motion 
and daily activities 
Genital 
tract 
Mild signs/symptoms, 
minimal pain on exam 
Moderate signs/symptoms with 
discomfort on exam 
Advanced signs like 
strictures, ulceration 
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1.4.4.6 Clinical features 
Clinically, cGVHD affects single or multiple target organs and produces a constellation 
of clinical manifestations (Filipovich, Weisdorf et al. 2005) with features resembling 
autoimmune and other immunologic disorders such as scleroderma, Sjögren syndrome 
and bronchiolitis obliterans. Symptoms generally arise within 3 years of allo-HSCT and 
are often preceded by aGVHD. The skin, conjunctiva, oral cavity, gastrointestinal tract 
and liver are variably affected in cGVHD. In addition to these more commonly 
involved systems, many other organ systems may be affected (Sullivan 1986).  
 
Table 1.4.4.5.2: Global scoring of cGVHD modified from NIH consensus project 
Score Features  
Mild 1-2 organs (excluding lungs) with maximum score of 1 
Moderate ≥ 1 site with organ score of 2 OR ≥ 3 sites with score of 1 OR lung score of 1 
Severe  Organ score of 3 OR lung score of 2 
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1.4.5 Oral chronic graft-versus-host disease 
The oral cavity is frequently involved in cGVHD and may, in some instances, be the 
primary or sole site of involvement (Woo, Lee et al. 1997).  The frequency of oral 
cGVHD has been well documented with 72% to 83% of patients with cGVHD 
demonstrating oral involvement, making it one of the most common sites affected by 
cGVHD (Schubert and Correa 2008). In recent studies, the oral cavity was found to be 
involved in varying degrees relative to stem cell source with oral involvement in 70% 
of PBSCT recipients and 53% of BMT recipients who had cGVHD (Pavletic S. Z, 
Smith L.M et al. 2005). These manifestations closely resemble, both clinically and 
histologically, those of common autoimmune disorders including scleroderma and 
Sjögrens syndrome and immune-mediated oral lichen planus. Any oral site may be 
affected and the degree of involvement may be extensive. Oral mucosal lesions can be a 
source of significant pain, and when extensive, may limit nutritional intake and impede 
the maintenance of oral hygiene (Imanguli, Alevizos et al. 2008).  
 
1.4.5.1 Mucosal lesions 
Diagnostic features, highlighted by the NIH consensus project, for oral cGVHD include 
lichen planus-like changes which typically present as fixed white striations and 
hyperkeratotic plaques.  Almost any oral site may be involved, however, the buccal 
mucosa, tongue and labial mucosa are most commonly affected (Treister, Woo et al. 
2005) (Figure 1.4.5.1.1). Sclerotic changes in the perioral tissues, in patients with 
sclerodermatous cutaneous cGVHD,  may result in a reduced oral aperture (da Fonseca, 
Schubert et al. 1998) hindering the provision of dental care and the maintenance of oral 
hygiene. Specifically, these classic mucosal changes mimic those seen in immune 
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mediated lichen planus whereas the fibrosis and restricted aperture resembles that seen 
with scleroderma (Imanguli, Alevizos et al. 2008). 
 
Other oral lesions frequently associated with cGVHD but based on the NIH criteria, are 
not diagnostic of oral cGVHD include mucosal atrophy, development of 
pseudomembranes, ulceration and mucoceles (Woo, Lee et al. 1997; Filipovich, 
Weisdorf et al. 2005). Clinically, atrophic lesions may demonstrate a vasculitis-like or 
telangiectatic appearance. Chronic GVHD involving the maxillary anterior gingiva may 
be characterised by atrophy with loss of stippling (Schubert and Correa 2008).  
Figure 1.4.5.1.2: ORAL GVHD. A. Oral mucosa. Lymphocytic infiltrate along basal layer (magnified x160). 
B. High-powered: apoptotic changes along the rete ridge (Treister, Woo et al. 2005; Shulman, Kleiner et al. 
2006) 
Figure 1.4.5.1.1: Oral lichenoid cGVHD. (A) buccal mucosa (B) labial mucosa (Schaffer 2006) 
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The diagnosis of oral cGVHD is most commonly based on clinical findings however 
specific histopathological findings of both the oral mucosa and glandular tissue may 
confirm the clinical diagnosis.  In 2006  the NIH Consensus Development Project 
Pathology Working Group (Shulman, Kleiner et al. 2006) provided an update on the 
interpretation of biopsy results in cGVHD and proposed histological criteria for GVHD. 
The minimal histological diagnostic criteria for oral mucosal cGVHD have essentially 
remained unchanged (Figure 1.4.5.1.2); features consist of localised or generalised 
epithelial changes which comprise of lichenoid interface inflammation, exocytosis, and 
apoptosis. The connective tissue is characterised by variable amounts of perivascular 
inflammation and lymphocytic infiltration with occasional subepithelial clefting (Woo, 
Lee et al. 1997). Histologically there may be little distinction between acute and chronic 
GVHD so mucosal biopsies must often be correlated with the clinical observations. 
 
Immunohistochemical studies have established that the infiltrate in cGVHD is 
predominately lymphocytes and macrophages (Imanguli, Alevizos et al. 2008). The 
ratio of CD8 T cells to CD4 T cells has varied between studies, with some reporting a 
predominance of CD8 T cells (Soares, Faria et al. 2005) and others a predominance of 
CD4 T cells (Nakamura, Hiroki et al. 1996). 
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1.4.5.2 Xerostomia and salivary hypofunction 
The effect of cGVHD on salivary gland secretions is well documented. Salivary gland 
dysfunction which arises in the acute stages following allo-HSCT are predominatly 
attributed to conditioning regimen toxicity, especially in the case of TBI, and can 
persevere for many months. Late changes are most often ascribed to cGVHD and 
clinically resemble the features of Sjögren syndrome (Coracin, Pizzigatti Correa et al. 
2006). Extensive involvement results in the total destruction of secretory units leading 
to permanent and profound salivary hypofunction (Schubert and Izutsu 1987). The most 
prominent risk factor which has been implicated in the aetiopathogenesis of cGVHD 
salivary gland disease is TBI (Hemidahl, Johnson et al. 1985). The reduction in salivary 
flow rate has been reported in the range of 55% to 90% in patients with cGVHD with 
the severity of hypofunction being proportional to the severity of systemic cGVHD 
(Schubert, Sullivan et al. 1984). Critically, patients report oral dryness as the second 
most distressing symptom at discharge and at 1 year after HSCT (Larsen, Nordstom et 
al. 2007). However, it has been reported that often the symptom of xerostomia does not 
correlate with the signs of salivary hypofunction; where clinical evidence may 
demonstrate a reduction in salivary flow in patients who do not complain of a dry 
mouth (Alborghetti M.R, Correa M.E et al. 2005). 
 
Saliva plays a major role in maintaining oral health and oral function. A decrease in the 
quantity or quality of saliva can have a profound effect on the incidence of dental 
decay, oral candidosis, the retention of dentures and mucosal friability not to mention 
the adverse impact on speech, swallowing and mastication. Salivary dysfunction in 
HSCT patients is often not exclusively due to cGVHD. Confounding factors include 
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ionizing radiation, prolonged chemotherapy and the polytherapy often required for the 
management of these patients. 
 
Histopathologically, glandular tissue in cGVHD show similar features to those shown 
in Sjögren syndrome, except there are fewer lymphocytes which are not organised in 
foci (Lamey, Lundy et al. 2004).The diagnostic histological features seen in cGVHD 
involving the salivary glands include: intralobular, periductal lymphocytic infiltration 
with or without plasma cells and exocytosis of lymphocytes into the intralobular ducts 
and acini (Figure 1.4.5.3). Individual ductal epithelial cell apoptosis, and destruction of 
acinar tissues  with periductal fibrosis is also often present (Soares, Faria et al. 2005; 
Shulman, Kleiner et al. 2006). The superficial mucoceles described in the oral cGVHD 
spectrum are most likely a result of GVHD induced inflammation and damage to the 
minor salivary gland ducts leading to duct obstruction and finally destruction (Schubert 
and Correa 2008). The lymphocytic infiltrate primarily contains T lymphocytes, with a 
slight predominance of CD8 T cells over CD4 T cells (Soares, Faria et al. 2005).  
 
 
Figure 1.4.5.2: (C) Minor salivary gland. Early lobular change shows focal periductal lymphocytic infiltrates.       
(D) High-powered: marked lymphocytic infiltration, focal destruction of epithelium(Treister, Woo et al. 2005; 
Shulman, Kleiner et al. 2006) 
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1.4.5.3 Dysgeusia 
Altered taste sensation (dysgeusia) is a common conditioning regimen-related 
phenomenon which typically resolves 1 to 2 months following HSCT (Comeau, Epstein 
et al. 2001). Dysgeusia and/or hypogeusia or ageuisa can persist or arise in the later 
stages following HSCT and is often coupled with the onset of cGVHD. Patients may 
report a rapid reduction in their sense of taste during periods of cGVHD flare or onset 
(Epstein, Raber-Drulacher et al. 2009). The epithelial-derived taste receptor cell has 
been suggested as an immune based target in this setting (Marinone, Rizzoni et al. 
1991). Importantly, calcineurin inhibitors commonly used in the management of GVHD 
(cyclosporine, tacrolimus) can also induce neurological changes which may results in 
dysgeusia (Schubert and Correa 2008). Patients commonly complain of taste changes 
which may be described as metallic, salty, sweet, sour or bitter. Furthermore, a 
reduction in the quantity of saliva seen where cGVHD involves the salivary glands, 
may further promote an altered taste perception due to the reduced capacity for saliva to 
act as a solvent.  
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1.4.6 Other commonly involved organs 
1.4.6.1 Cutaneous chronic GVHD 
Cutaneous changes seen in the spectrum of changes attributable to cGVHD can be of 
two main types, namely, lichenoid and sclerodermatous forms (Aractingi and Chosidow 
1998).  
 
Lichenoid cGVHD 
Lichenoid lesions are traditionally considered the early presentation of cutaneous 
GVHD however lichenoid lesions can precede, develop simultaneously with, or follow 
sclerodermatous changes (Andrews, Robertson et al. 1997). Cutaneous lichenoid 
cGVHD typically involves the periorbital regions, hands, forearms and trunk (Schaffer 
2006). Lesions appear as flat-topped, pink to violaceous, scaly papules. Rarely these 
changes extend to involve the glans penis and foreskin in males causing phimosis 
whereas in females, the vaginal mucosa may be affected, leading to stenosis (DeLord, 
Treleaven et al. 1999).  
 
Sclerodermatous cGVHD: Morpheaform 
In late stages, an often insidious progression to a sclerotic and even sclerodermatous 
stage may ensue. Early sclerodermatous lesions are also termed morpheaform lesions 
(Saurat 1981). Clinically these lesions present as localised patchy areas of firm, leathery 
and occasionally hyperpigmented plaques which typically involve the lower trunk 
(Schaffer 2006). With progression, lesions may coalesce and more closely resemble 
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scleroderma. Lichen sclerosis is the term given to the most superficial manifestation of 
sclerodermatous GVHD. These lesions appears as hypopigmented plaques with scaling 
and follicular plugging which typically favour the neck and trunk (Schaffer 2006).   
 
Sclerodermatous cGVHD: Eosinophilic Fasciitis 
A rare presentation of cGVHD is eosinophilic fasciitis which represents a deeper form 
of sclerodermatous cGVHD. The extremities are most commonly affected, with sparing 
of the hands and feet (Schaffer 2006).  The condition is typified by pain and oedema 
followed by induration with bullae and ulcerations typically developing on the 
overlying surface (Schaffer, McNiff et al. 2005). The tissue surface may appear rippled 
and demonstrate a cellulite-like appearance.  
 
Cutaneous cGVHD is often accompanied by dystrophic changes of the nails including 
vertical ridges, onycholysis and telangiectasia of the nail fold (Aractingi and Chosidow 
1998). Skin sclerosis is thought to potentially arise due to excessive tissue repair 
resulting from immunologic injury by effector lymphocytes (Janin-Mercier, Devergie et 
al. 1984) which leads to replacement fibrosis and with time, joint contractures and 
debility (Sullivan, Weiden et al. 1981). 
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1.4.6.2 Ocular 
Approximately 60% of patients with cGVHD develop ocular manifestations 
(Ratanatharathorn, Ayash et al. 2001).  The most common presentations include 
keratoconjunctivitis sicca, sterile conjunctivitis and uveitis (Franklin, Kenyon et al. 
1983).  Patients may complain of dry, gritty or painful eyes which may be associated 
with photophobia and thick lacrimal secretions. It is recommended that a Schirmer‟s 
test be performed routinely on all patients in the early stages of cGVHD to facilitate 
early diagnosis of xeropthalmia. Extensive ocular involvement may lead to serious 
ocular complications such as corneal epithelial defects and ulceration 
(Ratanatharathorn, Ayash et al. 2001). Frequent use of topical lubricants and protective 
eyewear is essential in its management. 
 
1.4.6.3 Gastrointestinal tract 
Gastrointestinal involvement is typically not a prominent feature of cGVHD. As seen in 
aGVHD, dysphagia, nausea, diarrhoea and insidious weight loss may be presenting 
symptoms. Oesophageal webs, ring-like narrowing along with strictures formation, 
evident on a barium contrast radiograph or endoscopic visualisation, are diagnostic 
features of GIT cGVHD (Filipovich, Weisdorf et al. 2005).  
 
1.4.6.4 Liver 
Cholestasis most commonly predicts the clinical emergence of liver cGVHD 
(Ratanatharathorn, Ayash et al. 2001). Due to the existence of numerous alternate 
triggers for cholestasis, liver biopsy is essential for the confirmation of hepatic cGVHD 
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(Filipovich, Weisdorf et al. 2005). Liver failure, due to cGVHD alone, is uncommon in 
long-term survivors (Ratanatharathorn, Ayash et al. 2001). 
 
1.4.6.5 Pulmonary  
Bronchiolitis obliterans has been identified as a diagnostic feature of cGVHD involving 
the pulmonary system (Filipovich, Weisdorf et al. 2005). Clinical features range from a 
chronic cough to dyspnoea and progressive airflow obstruction. Patients with 
bronchiolitis obliterans have a exceptionally poor prognosis, and are often non-
responsive to therapy with the end point of pulmonary cGVHD being pulmonary failure 
(Cooke, Krenger et al. 1998). Diagnosis is via pulmonary biopsy or clinical features 
such as poor pulmonary function or characteristic features on imaging.  
 
Haematopoietic and Immune Systems 
Markers of haematopoietc and immune system dysfunction are commonly associated 
with cGVHD however are not sufficient to support a diagnosis of cGVHD without 
diagnostic features in other organ systems. Cytopenias are common,. Specifically, 
lymphopenia (≤ 500/μL), eosinophilia (≥500/μL), hypogammaglobulinemia or 
hypergammaglobulinemia (Filipovich, Weisdorf et al. 2005).  A poor prognosis has 
been attributed to the development of thrombocytopoenia at the time of cGVHD 
diagnosis (Filipovich, Weisdorf et al. 2005). Clinically, the resulting immunodeficiency 
places the patient at high risk of a wide range of opportunistic infections and often 
death (Ratanatharathorn, Ayash et al. 2001). 
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1.5 Management 
The recently published NIH Working Group Report on Diagnosis and Staging defined 
that systemic therapy is indicated for the management of cGVHD when 3 or more 
organs are involved or, alternatively, when a single organ has a score of 2 or greater 
(Filipovich, Weisdorf et al. 2005). Other high-risk features such as thrombocytopoenia 
and the underlying reason for transplantation (malignant versus non-malignant) may 
also be considered when assessing the need for systemic therapy. Early intervention 
may circumvent progression to severe cGVHD however the implementation of therapy 
alone increases the likelihood of significant infections and consequent TRM. Standard 
cGVHD therapy consists of cyclosporine with corticosteroids however only 
approximately 70% of patients respond to this empirical therapy. Multiple alternatives 
for salvage therapy are utilised however there is no standard approach, with an average 
response of 35% (Baird and Pavletic 2006). Critically, standard management strategies 
leave patients severely immunocompromised, frequently leading to fatal infections and 
other morbid complications (Pavletic S. Z, Smith L.M et al. 2005). 
 
Therapeutic decisions for the management of oral cGVHD must be cognisant of the 
patient‟s global disease status and so often require planning with the treating physician. 
Pharmacological management of oral cGVHD may comprise of a single agent or may 
involve combinations of several agents which may be in topical or systemic form. 
Systemic therapy is often indicated in the treatment of severe oral cGVHD or where 
isolated oral lesions fail to respond to local measures. Primary treatment goals are to 
lessen pain, increase quality of life and circumvent further damage to the oral tissues. 
The effectiveness of various systemic therapies on oral cGVHD has not been 
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specifically studied with limited data in circulation on the therapeutic outcomes seen in 
oral cGVHD. There are no specific systemic agents tailored for the management of oral 
cGVHD. Often the selection of treatment will be determined by the availability of 
particular agents and formulations, patient acceptance and cost (Schubert and Correa 
2008).  
 
1.5.1 Systemic therapy in cGVHD 
Systemic immunosuppressive therapy is implemented for extensive cGVHD involving 
numerous organs or sites (Imanguli, Alevizos et al. 2008). Initial treatment generally 
entails systemic corticosteroid therapy (e.g. prednisone 1.0mg/kg/day) with or without 
cyclosporine (Schubert and Correa 2008). Currently there is no standard second line 
therapy of cGVHD recalcitrant to steroid therapy. Limitations in the prescription of 
systemic therapy include an amplified risk for opportunistic infections and the prospect 
of a reduced graft-versus-leukaemic effect (Imanguli, Alevizos et al. 2008). 
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1.5.1.1 Corticosteroids 
Corticosteroids, used therapeutically, are generally synthetic analogues of the 
glucocorticoid steroid hormones produced by the adrenal glands under the regulatory 
control of the hypothalamus and anterior pituitary. Synthetic steroid therapy is used as a 
replacement therapy for endocrine deficiency states and for many non-endocrine 
conditions; to suppress inflammation, allergy and, of specific relevance to GVHD, to 
suppress immune responses.  
 
Naturally occurring cortisol and synthetic glucocorticoids are lipophilic and rapidly 
diffuse into target cells and bind to a cytoplasmic glucocorticoid receptor. This 
receptor-drug complex enters the nucleus and binds to specific regulatory elements on 
target DNA molecules which cause the initiation or inhibition of gene transcription 
(Goldman and Ausiello 2007). Synthetic glucocorticosteroids, rather than 
mineralocorticoids, are preferred in this setting due to their higher receptor affinity, 
slower inactivation and little or no salt retaining activity. Several preparations are 
utilised with different potencies, anti-inflammatory activity and half lives (Table 
1.5.1.1). In the setting of GVHD, the major beneficial therapeutic effects of 
corticosteroid therapy are their immunosuppressive and anti- inflammatory properties. 
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The synthetic corticosteroids utilised in the management of GVHD are 
immunosuppressive via their impact on the activation, production, circulation, function 
and survival of leukocytes. There is a decrease in the number of monocytes, 
lymphocytes, eosinophils and basophils. Of particular relevance to GVHD this effect is 
more pronounced on T cells than B cells, with the activation of apoptosis especially on 
immature or activated T cells (Goldman and Ausiello 2007). A rise in neutrophil 
numbers in the peripheral circulation is evident, however trafficking is impaired. 
Corticosteroids also are potent anti-inflammatory agents due to the inhibition of the 
arachidonic acid metabolities, with interference with the cyclo-oxygenase 2 enzyme and 
phospholipase A2. Outcomes include the generalised reduction in pro-inflammatory 
cytokines and interleukins (IL-1, IL-2 IL-6, TNF-α) and the propagation of anti-
TABLE 1.5.1.1: Properties of  natural and synthetic steroids (Goldman and Ausiello 2007) 
Steroid Glucocorticoid 
effect 
Equivalent 
dose (mg) 
Mineralocorticoid 
effect 
Plasma ½ 
life (min) 
Biological 
½life (hr) 
Cortisone 0.8 25 2 30 8-12 
Hydrocortisone 1  20 2 90 8-12 
Prednisone 4 5 1 60 12-36 
Prednisolone 4 5 1 200 12-36 
Methylpred 5 4 0 180 12-36 
Triamcinolone 5 4 0 300 12-36 
Betamethasone 20-30 0.6 0 100-300 36-54 
Dexamethasone 20-30 0.75 0 100-300 36-54 
Aldosterone 0.1  400   
Fludrocortisone 10  400   
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inflammatory cytokines such as IL-4, IL-10 and IL-13. However, long term therapy 
with corticosteroids, defined as systemic therapy for over 3 weeks or a dose of 
prednisolone >10mg/ day, may result in significant suppression of normal adrenal 
function and is therefore associated with numerous significant adverse effects.  
 
Systemic corticosteroids predispose patients to opportunistic infections. This is further 
complicated by the anti-inflammatory properties which may mask many of the cardinal 
signs of infections, such as fever, inflammation and pain. Prolonged corticosteroid 
therapy is the most common cause of secondary hypoadrenalism, clinically presenting 
as Cushing‟s syndrome. Patients may develop a cushingoid facial appearance, which 
characteristically presents as a reddened (plethora) and swollen, moon face. This is 
exacerbated by weight gain, fluid retention and fat re-distribution from the extremities 
to the trunk and face. More significant metabolic complications include compromised 
glucose metabolism ranging from glucose intolerance to frank diabetes.  
 
Disturbances in bone metabolism are possible, leading to osteoporosis, avascular 
necrosis and pathological fractures. Prophylactic therapy for prevention of osteoporosis 
is generally prescribed for all patients on long-term steroid therapy. Corticosteroid 
therapy may also cause depression and psychosis. Critically, cGVHD has a propensity 
to require prolonged treatment with only 5% of patients ceasing immunosuppressive 
therapy at 1 year after diagnosis (Schubert and Correa 2008) which clearly places these 
patients at risk of serious adverse treatment related outcomes. Steroid-resistant cGVHD 
is associated with significantly reduced treatment success rates. 
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1.5.1.2 Cyclosporine  
Cyclosporine, a calcineurin inhibitor, functions by suppressing T cell proliferation by 
binding calcineurin and thereby preventing transcription of genes for IL-2, IL-2 
receptor and IFN-γ (Imanguli, Pavletic et al. 2006). Major adverse effects include 
nephrotoxicity, neurotoxicity and immunosuppression leading to increased incidence of 
infections, hypertension and impaired glucose tolerance. Specific to the oral cavity, 
cyclosporine is associated with generalised gingival overgrowth. 
 
1.5.1.3 Tacrolimus 
Tacrolimus functions similarly to cyclosporine however it binds to a unique protein- 
FKBP-12 (Jacobsohn and Vogelsang 2002). This second line agent may be used in 
place of cyclosporine especially in patients with significant liver cGVHD due to this 
drugs concentration in this organ (Jacobsohn and Vogelsang 2002). Adverse effects are 
similar to those reported with cyclosporine, however a higher incidence of 
nephrotoxicity is seen. Gingival overgrowth is less frequent with tacrolimus use. 
Critically, the Food and Drug Administration have issued a “Black Box” warning 
attached to the use of these agents due to the increase risk of solid cancers (SCC and 
lymphoma) seen following prolonged use. 
 
1.5.1.4 Sirolimus 
Sirolimus, a macrolide compound, with a similar but not identical mode of action as 
tacrolimus, functions by inhibiting T cell co-stimulatory pathways (Kahan 2001). 
Mounting evidence supports the use of this agent in steroid-refractory cases with a 63% 
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response rate observed in recent studies when combined with either tacrolimus or 
corticosteroids (Couriel, Saliba et al. 2005). The adverse event profile for infections and 
malignant neoplasms are similar to those reported with calcineurin inhibitors. Adverse 
reactions specific to sirolimus include renal impairment, thrombotic thrombocytopoenic 
purpura (TTP), hyperlipidemia and cytopoenias (Cutler, Antin et al. 2006). 
 
1.5.1.5 Mycophenolate mofetil 
Mycophenolate mofetil (MMF) is an immunosuppressive agent commonly utilised for 
aGVHD prophylaxis. MMF is also the most commonly prescribed agent for the 
management of cGVHD in steroid-refractory patients. Studies have shown this agent to 
be well tolerated with a reliable response rate of approximately 75% when used as 
therapy for refractory cases. MMF is a reversible inhibitor of inosine monophosphate 
dehydrogenase and is cytostatic for both T and B lymphocytes (Imanguli, Pavletic et al. 
2006). Gastrointestinal and haematological toxicity are the most frequent adverse 
effects and may limit the use of this agent (Imanguli, Pavletic et al. 2006). 
 
1.5.1.6 Extracorporeal photopheresis 
A method which is gaining popularity for the management of systemic cGVHD is 
extracorporeal photopheresis. The patient‟s mononuclear cells are isolated via apheresis 
and are then exposed to ultraviolet light A (UVA). The cells are subsequently re-infused 
into the patient. Although not fully elucidated, the suggested mechanisms of action 
include apoptosis of alloreactive T lymphocytes, normalisation of CD4/CD8 ratio and 
induction of regulatory T cell subsets (Fimiani, Di Renzo et al. 2004). Several small 
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studies have reported effectiveness in cGVHD particularly when the major site of 
involvement is the skin (Imanguli, Pavletic et al. 2006). Of particular interest, 
preliminary data has shown reasonable results in the management of oral GVHD 
(Imanguli, Pavletic et al. 2006) however the prolonged treatment time and the need for 
intravenous access are significant disadvantages. 
 
 
1.5.1.7 Hydroxychloroquine 
Hydroxychloroquine, an antimalarial agent, is widely used in many autoimmune and 
inflammatory disorders, most commonly lupus erythematosus and rheumatoid arthritis. 
Its mode of action is believed to be associated with altered antigen presentation, 
reduction in TNF-α, IL-2 and IL-6 activity, and lysosomal membrane stabilisation 
(Imanguli, Pavletic et al. 2006). The data supporting its applications in the management 
of cGVHD are few however the overall response rate in the oral cavity has been shown 
to be 38% (Gilman, Chan et al. 2000). The agent is generally well tolerated with 
nausea, vomiting and diarrhoea being the most significant side effects. 
 
1.5.1.8 Thalidomide 
Generally it was thought that thalidomide had limited efficacy in cGVHD, with its 
major applications being in inflammatory conditions such as Behcet‟s syndrome, 
ulcerative colitis and major aphthous ulceration. In recent years there has been a 
renewed interest in this immunomodulating agent in the treatment spectrum for cGVHD 
(Imanguli, Pavletic et al. 2006). The precise mode of action of thalidomide is unknown 
however observable outcomes include decrease in TNF-α activity, adhesion molecule 
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expression, inflammatory cell chemotaxis and CD4/CD8 ratio (Wood and Proctor 
1990). Adverse effects may be considerable with sedation being the most common. 
 
1.5.1.9 Methotrexate  
Immunomodulatory and anti-inflammatory properties of this antimetabolite are 
commonly exploited in the management of rheumatoid arthritis. Methotrexate, a folic 
acid antagonist, competitively inhibits dihydrofolate reductase and halts regeneration of 
intermediates needed for the conversion of deoxyuridylic acid to thymidylic acid. As 
rapidly dividing cells require abundant supplies of deoxythymidylate for the synthesis 
of DNA, methotrexate selectively prevents the division of these cells.  
 
Combined with cyclosporine, methotrexate is commonly used for the prophylaxis of 
aGVHD. Recently, several small studies have evaluated the efficacy of methotrexate in 
treatment of recalcitrant cGVHD. Data suggests that this agent deserves further 
investigation given its efficacy and favourable toxicity profile (Giaccone, Martin et al. 
2005), significant adverse effects being hepatotoxicity and oral mucositis.  
 
1.5.1.10 Other systemic therapies  
Emerging systemic agents are increasingly being trialled in recalcitrant cGVHD 
specifically, monoclonal antibodies, including anti-CD20 (rituximab) with promising 
results seen. The recombinant anti-TNF-α antibodies infliximab and etanercept along 
with the IL-2 receptor antibody (daclizumab) have also been tested in patients. 
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1.5.2 Topical and local therapy 
Topical preparations may be the sole therapy in oral cGVHD or may be part of a more 
complex management schedule. The advantages of topical or local therapies in oral 
cGVHD include the application of intensive treatments without necessarily increasing 
systemic immunosuppression and therefor maintaining the desirable GVL effects. 
Topical therapy also permits the avoidance of the complications, toxicities and drug 
interactions often associated with systemic treatments (Schubert and Correa 2008). 
These preparations are essentially identical to those utilised in the management of the 
oral manifestations of autoimmune and immune-mediated disorders such as oral lichen 
planus and vesiculobullous disorders. As mentioned with systemic therapies used in 
cGVHD, there is sparse literature on the efficacy of specific local and topical treatments 
and their usefulness relative to systemic treatments. Critical features needed in a topical 
or local therapy include substantivity, bioavailability when applied to oral mucosa, 
acceptable taste and a noninhibitory cost.  
 
1.5.2.1 Corticosteroids 
The most commonly used topical agents in the management of oral cGVHD are steroid 
preparations which may be formulated in a variety of media including rinses, gels and 
ointments (Schubert and Correa 2008). Typically, if there is extensive oral involvement 
or with areas difficult to access, such as the soft palate, a mouthrinse is considered the 
most appropriate vehicle. Where distinct lesions can be visualised and easily accessed, 
gels, ointments and creams may be effective. The various formulations and agents are 
listed in Table 1.5.2.1. Transient burning and oral candidosis are the most common 
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adverse effects of topical steroid therapy. Oral candidosis may lead to an acute flare in 
sensitivity and oral discomfort. Resolution is usually achieved with topical antifungal 
agents. When symptomatic oral GVHD impedes in activities of daily living and 
nutritional intake, topical analgesics, such as xylocaine viscous 2% (15ml swished 
30seconds/every 3hrs) may also be helpful.  
 
The available literature shows predictable results with dexamethasone solution 
(0.1mg/ml used 3-6x/daily). Wolff et al. showed a positive response in 11 out of 16 
patients with histological evidence of oral cGVHD treated with dexamethasone 
mouthwash (0.1 mg/ml dexamethasone, 4x/daily in combination with topical antifungal 
prophylaxis), with 9 patients showing complete resolution (Wolff, Anders et al. 2004). 
The authors observed that treatment was successful even in cases of where oral lesions 
were resistant to systemic steroids. Critically 12 of the 16 patients were receiving 
topical therapy as part of a multi-modality treatment for systemic cGVHD. Topical 
budesonide rinse (3mg capsule dissolved in 5ml water, 2-3x/daily) showed an overall 
success rate of 58% in 12 patients with oral GVHD in a study by Elad et al, however, 
interpretation of these results is difficult due to the concurrent use of systemic therapies 
(Elad, Or et al. 2003). The proposed benefits of using budesonide, a highly potent 
steroid, was its high topical-to-systemic activity unlike other corticosteroids such as 
beclamethasone and prednisolone (Brogdan and McTravish 1992). This quality is 
attributed to the low bioavailability when absorbed through mucosal surfaces and 
therefore associated with minimal risk for systemic side effects.  
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TABLE 1.5.2.1: Topical and local treatment for oral GVHD (Schubert and Correa 2008) 
Formulation  Specific agent Concentration  Instructions for use 
Rinses  Dexamethasone  0.1-0.4 mg/ml solution                  5-10ml swish for 3-5min 
then spit out. Repeat 3-6 
x/day 
Budesonide  0.3-0.6mg/ml solution 10ml swished for 15min 
then spit out. 2-4x/day 
Betamethasone 0.5ml tablet dissolved in 
10ml 
Held for 3min then spit out. 
Repeat 3-4x/day 
Prednisolone 3mg/ml 5ml swish for 4-6min then 
spit out. Repeat 3-6x/day 
Triamcinolone  1% aqueous solution 5ml swish for 4-6min then 
spit out. Repeat 3-6x/day 
Sprays and 
inhalers  
Beclamethasone  1-2 puffs without inhaling. 
Repeat 2-4x/day 
Fluticasone  As above 
Betamethasone  As above 
Triamcinalone   As above 
Gels, 
creams and 
ointments 
Clobetasol  0.05% cream, ointment, gel 
or solution 
Apply to lesion 2x/day 
Halobetasol  0.05% cream, ointment Apply to lesion 2x/day 
Fluocinonide  0.05% cream, ointment or 
gel 
Apply to lesion 2x/day 
Betamethasone  0.05-0.1% cream or 
ointment 
Apply to lesion 2x/day 
Triamcinalone 0.1-0.5% cream Apply to lesion 2x/day 
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1.5.2.2 Other immunomodulatory agents 
Cyclosporine rinse or gel has been described in the literature as a successful treatment 
in oral lichen planus along with other mucocutaneous disorders (Eisen, Ellis et al. 
1990). A number of small studies have explored the use of topical cyclosporine in the 
management of oral cGVHD showing a response rate between 45%- 75% (Epstein and 
Reece 1994; Epstein and Truelove 1996). Epstein et al. reported a 45% clinical 
response in a group of 11 patients with oral cGVHD who were shown to be refractory 
to topical corticosteroid therapy where the clinical response was measured as a 
reduction in total area of ulceration and erythema (Epstein and Reece 1994). Side 
effects are generally mild and consist of transient burning however topical cyclosporine 
is prohibitively expensive for routine use. 
 
Tacrolimus and pimecrolimus are newer calcineurin inhibitors. In its systemic forms, 
tacrolimus has been used successfully in the management of cGVHD for many years. 
Topical tacrolimus is widely used in the treatment of atopic dermatitis and cutaneous 
cGVHD. More recently, topical tacrolimus ointment (Table 1.5.2.3) has been 
investigated as a treatment alternative for oral cGVHD. A limited number of studies 
have been published with preliminary findings suggesting a therapeutic benefit with 
minimal adverse effects (Eckardt, Starke et al. 2004). However the Food and Drug 
Administration (FDA) have issued a “Black Box” warning assigned to the use of these 
newer agents due to the theoretical increased risk of malignancy, specifically SCC and 
lymphoma, in patients using these agents for cutaneous psoriasis. Thus, the applications 
of these agents are generally restricted. 
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Lastly, azathioprine, a purine analogue used extensively for the prevention of transplant 
rejection and inflammatory dermatological conditions, has been assessed as a topical 
agent for oral cGVHD. Azathioprine rinse and gel (Table 1.5.2.3) have been assessed in 
a small study where the patients recruited were known to be previously recalcitrant to 
both topical corticosteroids and cyclosporine. A 60% response rate over approximately 
16 weeks of treatment with topical azathioprine with concurrent systemic therapy was 
reported. Potential adverse effects identified in systemic therapy with azathioprine 
includes dose related marrow aplasia along with a suspected risk for second 
malignancies in the transplant setting (Schubert and Correa 2008). Due to the limited 
data on its topical use it is unknown if topical azathioprine use is associated with a risk 
for oral malignancy. 
 
1.5.2.3 Light-based therapies 
Exposure to UVA following the oral administration of 8-methoxypsoralen (PUVA) has 
been described for the treatment of several cutaneous conditions. Essentially, 8-
methoxypsoralen diffuses into the cell nucleus, causes cross-linkage of DNA once 
exposed to UVA, thus leading to cellular apoptosis. It has been suggested that rapidly 
proliferating cells, such as T lymphocytes and antigen presenting cells, may be 
particularly sensitive to the effects of PUVA (Yoo, Rook et al. 1996). PUVA is more 
commonly employed for the management of cutaneous GVHD however several case 
series have reported a beneficial response with local intraoral PUVA therapy for 
steroid-refractory oral cGVHD (Vogelsang, Wolff et al. 1996; Wolff, Anders et al. 
2004). Vogelsang et al. suggested a potential benefit of intraoral PUVA therapy in a 
small number of patients (Vogelsang, Wolff et al. 1996). More recently Wolff et al. 
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reported promising results when seven patients with recalcitrant oral cGVHD were 
treated with intraoral PUVA therapy using a flexible glass fibre extension. Of note, all 
but one patient received concurrent systemic immunosuppression. Overall 6 of the 7 
patients responded to intraoral PUVA therapy with 4 patients showing complete 
resolution of active oral cGVHD requiring a median of 36 treatments (range from 11-
92) (Wolff, Anders et al. 2004). Patients who responded to therapy remained stable over 
the 2-3 year review period. 
 
Common adverse effects associated with PUVA therapy include nausea associated with 
methoxypsoralen administration and phototoxicity. This is generally well managed with 
antiemetic pre-medication. Potential adverse effects include methoxypsoralen-
associated hepatotoxicity, requiring regular monitoring of liver function. Potential 
cataract development has been reported with UVA exposure following photosensitiser 
administration necessitating appropriate eye protection following ingestion of 
methoxypsoralen. The use of topical psoralens has been suggested as a method  of 
avoiding the side effects attributable to systemic administration (Al-Hashimi, Schifter et 
al. 2007). Of importance a long term side effect identified with cutaneous PUVA is the 
risk for cutaneous malignancies, particularly SCC and basal cell carcinoma, over an 
extended time frame of 10–20 years (Lindelof, Sigurgeirsson et al. 1991). At this stage 
there is insufficient data available to determine the actual risk for oral malignancy 
(Schubert and Correa 2008).  
 
Of significance, there has been increasing interest in the applications of ultraviolet light 
B (UVB), instead of UVA, to treat skin conditions. The proposed benefits of UVB 
(Table 1.5.2.3) include its efficacy without the addition of a photosensitising agent 
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combined with the fact that an increased malignancy risk has not been reported with 
UVB (Schubert and Correa 2008). Wackernagel et al. compared the efficacy of PUVA 
and UVB therapy in patients with diffuse oral lichen planus. Out of the 15 patients 
treated with PUVA 67% (n=10) showed a complete response following therapy 
whereas only 31% (n=4) of the 13 patients in the UVB group showed complete 
resolution. There was no statistically significant difference between the duration of 
treatment or number of treatments (Wackernagel, Legat et al. 2007). There is limited 
data on the application of UVB therapy in oral cGVHD. Elad et al. reported two cases 
of steroid-refractory oral cGVHD which were treated with UVB radiation. Both patients 
responded early and effectively, displaying only minimal side effects at a relatively low 
cumulative dose (Elad, Garfunkel et al. 1999). More work is needed on both the use of 
PUVA and UVB in the treatment of oral cGVHD. 
 
Lastly, the use of low-level laser therapy (LLLT) and CO2 laser treatment has been 
described in a small number of case reports (Table 1.5.2.3). The positive features of 
LLLT, include its regenerative effects and its immunomodulatory potentital 
demonstrated, in vivo, as inhibition of the proliferation of lymphocytes(Dyson, Agaiby 
et al. 2002). Chor et al. reported marked improvement in oral cGVHD lesions in a 
patient treated with LLLT (Chor, Mello de Azevedo et al. 2004). Elad et al. investigated 
the use of CO2 laser for pain control in oral cGVHD in a recent pilot study. Using a low 
power emission (1W) treatment was provided without local analgesia; patients reporting 
an immediate reduction in pain following 82% of sessions (Elad, Or et al. 2003). CO2 
laser emits infrared radiation at a wavelength of 10.6 mm. allowing high water and soft-
tissue absorption. The underlying mechanism for the analgesic effect seen with CO2 
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laser has not been fully elucidated. Explanations proposed include activation of c-fibers 
leading to induction of a central somatosensory response (Tran, Inui et al. 2002). 
Alternatively it has been postulated that there is a spinal inhibitory effect via peripheral 
nerve stimulation (Weng and Schouenborg 1996).  
TABLE 1.5.2.3: Alternative non-steroidal local therapies (Schubert and Correa 2008) 
Formulation Specific agent Concentration Instructions for use 
Rinse  
Cyclosporine  100mg/ml 5ml swished for several 
min, spit out.  3 x/day 
 
Azathioprine  5-10mg/ml 5-10ml swished for 3-5min, 
spit out. Repeat 2-6 x/day 
Gel or 
ointment 
Cyclosporine 0.5mg/ml Applied to lesions 2 x/day 
 
Azathioprine 5mg/ml in 3% 
methylcelluolose base 
1-2ml applied to lesion 3-4 
x/day 
 
Tacrolimus 0.1% gel Apply on gauze, hold on 
lesion 15-20min.  2 x/day 
Phototherapy  
PUVA 0.3mg/kg psoralen is given 
orally followed by 0.5-6.0 
J/cm2 UVA radiation  
UVA dose increased (by 
0.5 J/cm
2
) as tolerated. 3-4 
x/week until resolution 
 
UVB 0.02mJ/cm
2 
 Escalating doses by 
0.02mJ/cm
2
 every 4
th
 use 
 
Low-level laser 
therapy 
632-660nm, 2-3J/cm
2 
per use Treat 2-3 x/week until 
healed 
 
Carbon dioxide 
laser 
Defocused 1W Held 1cm from surface for 
2-3 seconds. Surface kept 
moist 
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1.5.2.4 Others  
Topical thalidomide in an ointment and rinse formulation, are currently undergoing 
investigation (Phase II trial NIH) for applications in oral cGVHD based on its anti-
inflammatory effects, specifically, reduced TNF-α levels which have been proposed to 
decrease cGVHD-related stomatitis and oral pain (www.clinicaltrials.gov 2009). 
 
1.5.3 Specific therapy for salivary dysfunction associated with oral cGVHD 
Replacement of saliva in salivary hypofunction may range from simple measure such as 
frequent sips of water and water vapourisers to the prescription of sialogogues (Table 
1.5.3). Temporary relief may be achieved through the use of oral moisturisers and saliva 
substitutes. Artificial saliva may have many different preparations with unique qualities 
and few studies have compared their effectiveness (Table 1.5.3). Visch et al. evaluated 
the commercially available mucin-based products and compared their efficacy to the 
carboxymethylcellulose (CMC) preparations. In general, it was found that the mucin-
containing products were best tolerated and preferred by patients (Visch, Gravenmade 
et al. 1986). Most available products are CMC preparations which increase the viscosity 
but do not reproduce the physical properties of saliva. Critically, artificial saliva 
products do not replace the many salivary macromolecules critical to the varied 
functions of saliva (Agha-Hosseini, Mirzaii-Dizhag et al. 2007). Patient acceptance of 
these product is often hindered by taste, viscosity, lubrication properties, and poor 
retention in the mouth (Epstein and Stevenson-Moore 1992). Longer lasting results may 
be seen with the use of sialogogues such as pilocarpine hydrochloride and cevimeline, 
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which directly stimulate the salivary glands to increase output however, functional 
glandular tissue is required for successful outcomes of therapy.  
 
Pilocarpine is a natural alkaloid (nitrogen containing compound) which is extracted 
from the South American shrub of the genus Pilocarpus. It is a hygroscopic, odourless, 
bitter powder which is soluble in water and alcohol. A direct acting muscarinic agonist, 
Pilocarpine functions to enhance the effects mediated by acetylcholine in the central 
and peripheral nervous system, a cholinergic effect, as well as producing a mild beta-
agonist effect. By activating muscarinic receptors, pilocarpine hydrochloride, can 
increase the secretions by the exocrine glands including the salivary, lacrimal, sweat, 
gastric, pancreatic and intestinal glands along with the mucous cells of the respiratory 
tract. Pilocarpine is most commonly prescribed for the treatment of glaucoma as a 
locally acting miotic agent of the papillary muscles. Supplementary uses of pilocarpine 
are seen in the numerous conditions associated with salivary hypofunction, namely, 
Sjögrens syndrome and more recently salivary hypofunction in cGVHD (Table 1.5.3).  
 
Along with the desired effect of causing an increase in salivation, pilocarpine 
hydrochloride may also cause some undesirable effects.  Common adverse effects 
include urinary urgency, due to the relaxation of the sphincter of the bladder, along with 
an increase in perspiration and lacrimation. More significant adverse effects include an 
increase in airway resistance and secretions due to a rise in bronchial smooth muscle 
tone along with bradycardia and postural hypotension, due to the co-stimulation of the 
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muscarinic receptors of the heart. Pilocarpine should therefore be avoided in patients 
with significant pulmonary or gastrointestinal cGVHD.  
 
Several studies have shown promising results of pilocarpine therapy in patients treated 
with head and neck radiotherapy and recently a number of small studies have looked at 
outcomes of therapy in patients with salivary cGVHD. Agha-Hosseini et al. reported a 
statistically significant difference in salivary flow rate 1hour following administration 
of pilocarpine hydrochloride (5mg oral pilocarpine, Salagen™). There was no 
difference in salivary flow rate between the study group and control when further time 
had elapsed (7 days after completion) (Agha-Hosseini, Mirzaii-Dizhag et al. 2007). 
Nager et al. reported positive and enduring increases in both subjective and objective 
parameters of salivary flow following therapy with pilocarpine hydrochloride 
(30mg/day). Of interest, when treatment was ceased, there was a rapid reduction of 
salivary flow to baseline levels however when medication was reinstituted, a rapid, 
profound increase was seen. The authors concluded that for the positive effects to be 
sustained continuous administration of pilocarpine is necessary (Nagler and Nagler 
1999). Cevimeline (Evoxac™) is another parasympathomimetic agent which has been 
applied in the management of salivary hypofunction in cGVHD. Cevimeline is 
associated with a longer duration of action (Fox 2004) however is not available in 
Australia at this stage.  
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Table 1.5.3: General dental care and  therapies for xerostomia (adapted from (Schubert and Correa 2008) 
 Composition Examples  
Saliva 
substitutes 
1. Aqueous ion solutions   
2. Aqueous ion + carboxymethylcellulose Oralube® (Orion) spray                                
- CMC base with electrolytes                        
- pH 5-7 
Aquae® (Hamilton) spray                            
- pH 5.5                                                         
- ≤4m on PBS for palliative care 
patients                                         
3. Mucin-containing solutions  
4. Glycoprotein-containing  
5. Enzyme containing gels Oralbalance® (Laclede Inc) gel                    
- CMC base with enzymes 
lactoperoxidase, lysozyme, 
lactoferrin                                           
- pH 6.5 
Salivary 
stimulants  
Non-pharmacological agents  
o Sucking on hard sweets (sugar free)                            
o Bitter or acidic substances (discouraged in 
dentate patients, may cause erosion) 
Biotene Dry Mouth Gum                      
Extra sugarfree gum 
 Pharmacological 
o Pilocarpine hydrochloride: 5mg/5ml, 5ml QID po. Increase by 2.5mg/5ml if tolerated 
o Cevimeline: not available in Australia 
 
Decay 
prevention 
Fluoridated toothpaste  
o Avoid foaming agents e.g. sodium lauryl sufate 
(SLS), may irritate mucosa 
o Strong flavourings (mint, cinnamon) may 
irritate 
o Avoid acidulated phosphate preparations as 
must etch tooth surface to be effective 
Biotene Dry Mouth Toothpaste 
(SLS free) 
NeutraFluor 5000 Plus (Colgate) 
1.1% w/w Sodium Fluoride 
Gel-Kam (Colgate) gel with 0.4% 
stannous fluoride (may cause 
staining) 
PreviDent (Colgate) gel. 1.1% 
Sodium Fluoride (neutral pH) 
Chlorhexidine mouthwash or gel 
o Cationic bisguanide  
o Broad spectrum antimicrobial with good 
adsorption onto mucous membranes 
o Effective against aciduric oral bacteria i.e. 
mutans streptococcus + lactobacilli (Hugo 1964) 
(Hugo and Longworth 1964) 
Savacol® mouthwash (Colgate) 
0.2% with 12% alcohol                                  
Plaqacide® mouthwash (Oral B) 
0.2% 
Curasept® mouthwash (Curaden) 
0.05%, 0.12%, 0.2%  
Curasept® (Curaden) gel 0.2% 
General 
oral and 
dental 
care 
Avoidance of  
o Known irritants such as spicy, acidic, hot food or carbonated beverages 
o Alcohol containing mouthwashes due to the associated desiccation of oral tissues 
o Xerogenic medications such as tricyclics antidepressants etc 
o High sugar/ acid diets which will potentiate rampant decay and erosion of enamel 
Patients are encouraged to maintain immaculate oral hygiene with regular dental reviews 
every 3-6months so early intervention and preventative measures may be implemented. 
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1.6 Prognosis 
Chronic GVHD is associated with a reduced quality of life (Sutherland, Fyles et al. 
1997), impaired functional status (Duell, van Lint et al. 1997), the need for prolonged 
immunosuppressive therapy and reduced survival (Lee, Klein et al. 2002). This is the 
chief cause of late TRM following allogeneic HSCT with a 5-year survival rate in 
patients with cGVHD as low as 40% in certain populations (Baird and Pavletic 2006). 
Chronic GVHD accounts for roughly one-quarter of deaths in long term HSCT 
survivors for leukaemia and two-thirds of deaths in aplastic anaemia (Ratanatharathorn, 
Ayash et al. 2001). Even in long term survivors with cGVHD there is significant 
morbidity and reduction in quality of life. Despite these unfavourable outcomes, the 
presence of cGVHD is linked with fewer leukaemic relapses. Lee et al. reported a low 
relapse rate of 8-9% following the onset of cGVHD (Lee, Klein et al. 2002) which is 
thought to reflect the GVL effect. Clearly, the impact of cGVHD on survival depends 
on the balance between its adverse and desirable effects. 
 
Numerous factors which are associated with a higher risk of TRM in cGVHD patients 
have been identified; these include the presence of cGVHD in multiple organs, a 
reduced clinical performance score, thrombocytopoenia at the time of cGVHD 
diagnosis and the progressive development of cGVHD on the background of pre-
existing aGVHD (Filipovich, Weisdorf et al. 2005). Lee et al. also reported that TRM 
increased with increasing global severity of cGVHD with a relative risk of 0.6 in mild 
cGVHD relative to 6.3 in severe cGVHD (Lee, Klein et al. 2002). Thus, it is clear that 
although some degree of cGVHD offers a protective element via the GVL effect, when 
severe, cGVHD is the primary cause for non-malignant mortality following HSCT.  
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Chapter 2: AIMS 
 
The aims of this treatise are to: 
1. Assess the extent and range of dental/oral long-term complications following 
allogeneic human stem cell transplantation 
2. To explore factors associated with the dental/oral complications of allogeneic human 
stem cell transplantation. 
 
Chapter 3: MATERIALS AND METHODS 
 
3.1 Study design and inclusion criteria 
All surviving patients, who had received an allogeneic HSCT (allo-HSCT) in the 
Westmead Hospital Bone Marrow Transplant Unit (BMTU) during the period of 
January 2003 to July 2008, and were at least 100 days post-transplant, were sent an 
invitation to participate in this research. Two hundred and sixty nine patients underwent 
allo-HSCT within the designated time period. Of those, one hundred and thirty nine 
patients were still living at the commencement of this study. These 139 patients made 
up the potential study population and were invited to participate.  
 
The initial contact letter described the study aims and advised that they would be 
approached at their next clinical appointment with more information and invited to 
participate in this study. Participation was entirely voluntary. The sample included only 
those candidates who were at least 100 days (3 months) post allo-HSCT in an attempt to 
examine only the patients who may present with chronic, not acute complications, of 
transplantation.  
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3.2 Transplant Database Questionnaire  
A standardised Transplant Database Questionnaire was completed for each patient who 
consented to participate. Information obtained from the medical file was divided into 
1. Background information pertaining to diagnosis and details pertaining to the 
HSCT 
2. Acute complications associated with HSCT 
3. Chronic complications associated with HSCT 
 
Demographics collected on each patient included; the original haematological diagnosis 
which led to HSCT, the number of years since HSCT and details of the transplant. This 
included the stem cell source, the nature of the donor (MUD or sibling donor), the 
conditioning therapy used, the use of TBI and the GVHD prophylaxis regimen. The 
second section of this Questionnaire focused on any early complications of HSCT, 
particularly mucositis and GVHD. The grade (severity) of mucositis was based on the 
World Health Organisation (WHO 1979) terminology criteria for common adverse 
events (Table 3.2). Details of aGVHD were gathered from the medical records, namely, 
the organs involved, the grade (Glucksberg 1994, Table 4) and management schedule.  
 
Table 3.2: The World Health Organisation mucositis grading criteria 
Grade                                          Clinical features  
0 - 
1 Soreness/erythema 
2 Erythema, ulcers but able to eat solids 
3 Ulcers but requires liquid diet 
4 Oral alimentation not possible 
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SYDNEY WEST 
Area Health Service 
 
Form 1: TRANSPLANT DATABASE QUESTIONNAIRE 
 
Patient details: 
Participant‟s name      Male / Female 
Date of birth       MRN 
 
Haematological transplantation: 
Initial diagnosis 
Date of diagnosis 
Type of transplant  Sibling   Unrelated donor 
Stem cell source Bone marrow  Peripheral blood   Umbilical  
Conditioning   Reduced intensity Myeloablative 
 TBI   Yes  No 
 Chemotherapy 
 
Mucositis    Yes   No 
Grade    I  II  III  IV 
 
Acute GVHD   Yes   No 
Time of onset   Day +  
Organs involved  Skin   Liver   Gut 
Disease severity  I  II  III  IV 
Management   Steroids  Other 
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SYDNEY WEST 
Area Health Service 
 
Form 1: TRANSPLANT DATABASE QUESTIONNAIRE 
 
 
Chronic GVHD:   Yes   No 
Time of onset 
Grade  
 
Organs involved: 
Dermatological   Yes No  Clinical Dx Histology 
Ocular     Yes No  Clinical Dx Histology  
Hepatic    Yes No  Clinical Dx Histology 
Haematopoietic   Yes No  Clinical Dx Histology 
Musculoskeletal   Yes No  Clinical Dx Histology 
Gastrointestinal   Yes No  Clinical Dx Histology 
Oral     Yes No  Clinical Dx Histology 
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3.3 Participant Questionnaire  
Patients who agreed to participate in this study were seen in the Oral Medicine Clinic at 
the Westmead Centre for Oral Health, Westmead Hospital. On the day of examination 
an assessment was made using the Participant Questionnaire (Form 2) and the Oral 
Examination Form (Form 3). The Participant Questionnaire was completed by the 
researcher and detailed the responses to a series of questions about the experience of 
transplantation. Questions centred on  
1. Assessment of subjects perceived oral complications associated with HSCT 
2. Identification of potential confounding factors such as a previous diagnosis of 
Scleroderma or radiotherapy to the head and neck not associated with TBI 
3. Questions pertaining to pre-transplant dental assessment and the current 
regularity of dental reviews 
4. Each patient‟s assessment of the adequacy of information, pre-transplant, 
relating to potential oral complications. 
 
The main purpose of the Participant Questionnaire was to obtain qualitative data on the 
severity and spectrum of subject‟s oral complications following HSCT. Specific 
questions explored alterations in the patient‟s oral aperture, taste, salivary function, 
decay rate and the overall impact these adverse effects had on their quality of life. 
 
The questionnaire also examined transplant recipient‟s views regarding the adequacy of 
pre-transplant education about the long-term oral complications of HSCT, including 
their view on the optimal time for the delivery of education about oral health. This data 
was hoped to allow for future adjustment of educational methods to align with overall 
patient need.  
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SYDNEY WEST 
Area Health Service 
 
Form 2: PARTICIPANT QUESTIONNAIRE 
 
Patient details: 
Participant‟s name 
Medical record number 
 
Limited medical history: 
Current medications related to transplant 
 
Other conditions: 
Sjögrens syndrome    Yes No 
Systemic sclerosis    Yes No 
Oral lichen planus    Yes No 
Radiotherapy to the head and neck  Yes No 
 
Chronic GVHD  Yes No 
 
Subjective oral complications: 
Xerostomia    None Mild Moderate Severe 
Reduction in oral aperture  None Mild Moderate Severe 
Alteration in taste   None Mild Moderate Severe 
Impact in quality of life  None Mild Moderate Severe 
Accelerated decay   None Mild Moderate Severe 
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SYDNEY WEST 
Area Health Service 
 
Form 2: PARTICIPANT QUESTIONNAIRE 
 
Pre-transplant: 
Did you have a dental assessment pre-transplant   Yes No 
How regularly were you seeing a dentist prior to transplant 
 
Current oral management strategies: 
 
 
Current regularity of dental reviews  3m 6m 12m >12m 
 
If not, why are you not seeing a dentist regularly? 
 Cost  Inconvenience  Unaware of need Afraid 
Where you aware of possible oral complications after transplant?  Yes No 
How was the information attained? 
 Transplant doctor Nurse  Dentist  Patient education day 
 BMT education book  Other patient  Friends/Family 
 
Was this information useful? 
Was the information sufficient? 
Would you prefer the information relating to long-term oral complications at 
Education day  Pre-transplant  Outpatient review  If need arises 
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3.4 Oral Examination Questionnaire 
Following the completion of the Participant Questionnaire each subject underwent a 
clinical examination which focused on the assessment of the oral and peri-oral tissues. 
This examination screened each participant for the spectrum of oral complications 
possible after allogeneic HSCT through assessment of; 
1. Maximal unassisted oral aperture (interincisal distance) 
2. Salivary hypofunction 
3. The presence and location of mucosal pathology, including mucosal GVHD  
4. Past diagnosis of an oral, peri-oral malignant or pre-malignant lesion 
 
Maximal oral aperture was measured in millimetres from the incisal edge of the most 
vertically aligned maxillary central incisor to the labioincisial edge of the opposing 
mandibular incisor. The degree of incisal overlap was then added to the documented 
maximal opening to get the final recording. The measurements taken allowed each 
subject to be categorised relative to their degree of opening. Normal oral aperture was 
taken as any measurement higher than, and inclusive of, 50 millimetres (mm). The 
literature shows that the mean maximal unassisted opening falls in the range of 50mm 
to 60mm in normal, healthy individuals (Posselt 1962; Dworkin and LeResche 1992). 
Subjects were placed into one of five categories (normal, mild, moderate, severe) 
according to the severity of the reduction in unassisted maximal opening (Naylor, 
Douglass et al. 1984) (Table 3.4.1). 
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Table 3.4.1: Classification of the maximal unassisted oral aperture 
Degree of reduction in oral aperture Interincisal measurement (millimetres) 
Normal  51 – 60 
Mild  50 - 41 
Moderate 40 - 31 
Severe  < 30 
 
Salivary hypofunction was established using a combination of visual inspection and the 
Saliva Check Buffer kit (GC Corporation). Resting, pooled salivary consistency was 
visually assessed by the examiner and subjects were placed in one of three groups. 
Salivary consistency was recorded as frothy/bubbly or sticky/frothy which represented 
saliva of increasing viscosity. Watery/clear saliva was indicative of saliva of normal 
viscosity.  
 
The quantity of stimulated saliva was assessed using the Saliva Check Buffer kit. The 
subject was asked to chew on a piece of unflavoured wax to stimulate salivary flow. 
After 30 seconds had elapsed the subject was asked to expectorate any accumulated 
saliva. The subject then continued to chew for a further 5 minutes, expectorating all 
saliva, at regular intervals, into the measuring cup provided. The volume measured was 
the liquid component only, not any supervening frothy material, and this was read at the 
base of the meniscus. The final amount of saliva produced was measured from the 
millilitre markings on the measuring cup provided in the kit. Based on the normal 
stimulated salivary flow rate of 1ml/min – 1.6ml/min, subjects were grouped according 
to the total amount of stimulated saliva produced over this 5 minute period (Table 
3.4.2). 
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Table 3.4.2: Quantity of stimulated saliva over a 5 minute period 
Quantity (millilitres) Category  
< 3.5 ml Very low 
3.5 – 5.0 Low 
> 5.0 Normal 
 
The sample collected was then utilised to analyse the buffering capacity of each 
subject‟s stimulated saliva. Using a disposable pipette, saliva was drawn up and then 
dispensed onto the Buffer test strip (Figure 3.4.1). The Buffer test strip was made up of 
three identical test squares with one drop of saliva placed on each of the three test 
squares. Results were recorded after a two minute period. The colour of each of the 
three test squares ranged from green to blue and through to red. Colour readings were 
calibrated against the colour table provided. Saliva with a normal buffering capacity 
will turn each test square green, intermediate results will appear blue and poor buffering 
is represented via a red colour. Each of the three test squares are allocated a number 
from zero to 4 depending on the resulting colour (Table 3.4.3.1) creating a 12 point 
scale. 
 
 
 
 
 
 
 
 
Figure 3.4.1: Instruments to test salivary 
buffering capacity 
Figure 3.4.2: Buffer test strip after 2 minutes 
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Table 3.4.3: Conversion table of Buffer test strip  
Colour of each square at  2minutes Points  
Green  4 
Green / Blue 3 
Blue 2 
Blue / Red 1 
Red 0 
 
Conversion values for each square were summated, the final value placing each subject 
into one of three categories for salivary buffering capacity (Table 3.4.4).   
 
Table 3.4.4: Buffering capacity of the collected stimulated saliva  
Combined total Buffering capacity of collected saliva 
0 - 5 Very low 
6 - 9 Low 
10 - 12 Normal / High 
 
Finally, peri-oral and intra-oral tissues were visually assessed using a dental mirror and 
gauze. Changes such as lichenoid lesions, sclerodermatous change and lesions 
suspicious for pre-malignancy/malignancy were described and recorded 
diagrammatically. Subjects were questioned regarding any past diagnosis of oral, peri-
oral malignant or pre-malignant lesions. Statistical analysis was carried out using the 
Pearson Chi-Square test and Fisher‟s Exact Test where appropriate. 
 
Ethics clearance was received by the NSW Health Human Research Ethics Committee 
– Sydney West Area Health Service, Westmead Campus.   
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Lichenoid lesions  Yes No 
Sclerodermatous change Yes No 
Candidosis   Yes No 
Notes: 
 
 
Previous diagnosis of oral malignancy 
 Yes No 
 Date of diagnosis: 
 Site: 
SYDNEY WEST 
Area Health Service 
 
Form 3: ORAL EXAMINATION 
 
Patient details: 
Participant‟s name 
Medical record number 
 
Oral examination: 
Maximal oral aperture (mm) 
Resting saliva consistency  Sticky, frothy  Frothy, bubbly Watery 
Stimulated saliva over 5minutes (ml)  <3.5  3.5 - 5  >5ml 
Buffering capacity    0 - 5  6 - 9  10 - 12 
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Chapter 4: RESULTS 
4.1 Patient sample  
Two hundred and sixty nine patients underwent allo-HSCT during the period of January 
2003 to July 2008, and were at least 100 days post-transplant. Of those, one hundred 
and thirty nine patients were still living at the commencement of this study. These 139 
patients made up the potential study population and were invited to participate. A 
further three subjects deceased prior to examination and thirty eight subjects declined 
participation primarily due to distance between their residence and the Westmead 
Hospital BMTU. The study population was therefore comprised of eighty eight subjects 
(Figure 4.1). 
 
Figure 4.1: Study population characteristics 
 
Subjects ranged in age from 19 to 65 years however the age at transplantation was most 
commonly between 50 and 65 years (39.8%), followed by 30 to 39 years (23.9%). Of 
the 88 subjects seen the majority were male (n=65). There was a range of underlying 
diseases which lead to the application of HSCT (Table 4.1) with over half of the 
subjects receiving HSCT on the background of AML (55.7%). Clearly, as a direct result 
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of the introduction of the targeted therapy, imatinib mesylate (Glivec™) in 2000 for the 
treatment of CML, there has been a significant decline in the number of allogeneic 
HSCT for this condition. The most recent ABMTRR and EBMT data is based on 
patient activity in 2004 and a small but considerable proportion of patients still received 
allogeneic transplantation for the treatment of CML. This practice is now not current 
clinical practice, reflected in this study population where no subjects had received 
allogeneic transplantation for CML.  
 
  
 
Haematopoietic stem cells were harvested from the peripheral blood, bone marrow or 
umbilical cord tissue. The vast majority of subjects received PBSCT (79.5%), followed 
by BMT (15.9%), with only a small group receiving UC transplants (4.5%). The greater 
part of this population had sibling donors (71.6%) with a minority requiring a MUD 
(28.4%). More than half of all transplants were myeloablative (59.1%) with TBI-based 
conditioning regimens being the most frequently applied (36.4%) followed by the 
combination of Busulphan/Cyclophosphamide (23.9%). received a combination of 
cyclosporine and methotrexate as GVHD prophylaxis (79.8%). 
Table 4.1: Initial diagnosis prior to HSCT 
Diagnosis  Number of subjects Percentage 
Acute myeloid leukaemia 49 55.7 
Acute lymphoblastic leukaemia 11 12.5 
B-cell non-Hodgkin‟s lymphoma 13 14.8 
Myeloproliferative disorder 9 10.2 
Other 6 6.8 
Total 88 100 
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4.2 Acute complications 
4.2.1 Mucositis 
Mucositis was frequently encountered in this population. Of the subjects where this data 
was available (n=69), 69.6% experienced some degree of mucositis. The severity was 
evenly distributed between those which were recorded as Grade 1-2 (30.4%) and those 
which were Grade 3-4 (32.1%). Mucositis was more common in participants with  
myeloablative transplants (P<0.001) and a conditioning regimen involving TBI 
(P=0.006) or busulphan combined with cyclophosphamide (P=0.004). The source of 
stem cells (PBSCT, BMT or UC) did not statistically predict the development of 
mucositis. 
 
4.2.2 Acute graft-versus-host disease 
Acute GVHD was a regular complication following transplantation with 52 subjects 
(59%) being diagnosed with some degree of aGVHD. Of note, this information was not 
available for 23 subjects. The risk factors identified for the development of aGVHD 
included the use of myeloablative conditioning regimens (including TBI) where 68.6% 
of subjects who received myeloablative conditioning developed aGVHD, relative to 
44.4% with RIC (P=0.024). The use of a sibling or MUD was also significantly 
associated with the development of aGVHD (P=0.01). Fifty percent of subjects who had 
sibling donors developed aGVHD relative to 80% with MUD transplants. A history of 
mucositis was also an independent variable, where 70.2% of subjects who had 
mucositis went on to develop aGVHD relative to 42.9% of subjects who did not have 
mucositis (P=0.032). When recorded, the onset of aGVHD ranged from 14 to 126 days 
after HSCT with 86.5% of subjects with aGVHD being diagnosed between 30-100 days 
after transplantation.  
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The majority of subjects had aGVHD of Grade 1-2 severity with only 6.2% of subjects 
experiencing Grade 3-4. TBI was the only features of transplantation that showed a 
significant association with the grade of aGVHD (P=0.02). Of note, age at 
transplantation, sex or stem cell source did not predict aGVHD or its severity. 
Clinically, the skin was most commonly affected in isolation (29%); multiple organ 
involvement was seen in 23% of subjects. 
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4.3 Chronic complications 
4.3.1 Incidence and risk factors 
Chronic GVHD arose in 64 of the 88 subjects (72.7%) after transplantation. Data 
pertaining to the grade of cGVHD was available for only 44 of these subjects with 
70.5% of these subjects having limited disease as opposed to 29.5% who had extensive 
involvement. The onset of cGVHD was primarily clustered over the first 3-12 months 
after transplantation (Chart 4.3.1) however a few subjects did develop cGVHD as long 
as 30 months after transplantation. Subjects were more likely to develop cGVHD if they 
had a pre-existing diagnosis of aGVHD (P=0.001) with 86.3% of subjects with aGVHD 
going on to develop cGVHD in comparison to only 52.8% of subjects who did not have 
aGVHD. Of interest, no other factors were found to predict the onset of cGVHD 
including age at transplantation, sex, transplant type, donor type, myeloablative 
conditioning or a history of mucositis. 
 
 
 
0
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0-100 days 3-6 months 6-12 months > 1 year
Number of 
subjects
Time since HSCT
Chart 4.3.1: Onset of chronic GVHD
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4.3.2 Clinical presentation 
In those with chronic GVHD the most commonly involved organs (Chart 4.3.2.1) 
included the skin (70.3%), mouth (56.3%) and liver (39%). Diagnosis of both cutaneous 
and oral cGVHD was primarily based on clinical features (63.6% and 94.4% 
respectively) unlike gastrointestinal chronic GVHD, where histology was the basis of 
diagnosis in 75% of cases.  
 
The clinical spectrum of oral cGVHD was inclusive of mucosal cGVHD, salivary 
hypofunction and reduced oral aperture. The risk factors identified for the development 
of oral GVHD included the presence of cutaneous cGVHD (P<0.001). Subjects who 
had cutaneous cGVHD were much more likely to also have oral cGVHD (60%) where 
only 20.9% of subjects developed oral cGVHD without cutaneous involvement. Similar 
patterns were seen with hepatic and ocular GVHD (Chart 4.3.2.2). Oral cGVHD was 
also more likely to develop in subjects with a history of aGVHD (P=0.015). However 
the development of oral cGVHD was not associated with a history of mucositis 
(P=0.675).  
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Oral
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Organs 
involved
Chart 4.3.2.1: Frequency of  individual organ involvement in chronic GVHD
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4.3.3 Results for the subjective oral complications after transplantation 
Subjects were investigated for both subjective and objective features of long-term oral 
complications after HSCT. Participants made their own assessment of any oral changes 
they ascribed to the transplant process. The specific subjective variables analysed were; 
a sensation of dry mouth (xerostomia), reduced oral opening, increased decay, reduced 
taste and the impact these factors had on each subject‟s quality of life (Chart 4.3.3.1).  
 
4.3.3.1 Xerostomia 
Forty four percent of subjects (n=39) reported oral dryness with 43.6% (n=17) of these 
subjects grading their degree of xerostomia as moderate to severe. The next most 
commonly reported complaint a reduction in taste (20.4%), closely followed by the 
subject‟s perception of accelerated decay rate (19.3%) (Chart 4.3.3.1). Interestingly, 
only 13 subject‟s (14.7%) thought these factors impacted on their quality of life. 
 
4.3.3.2 Dysgeusia 
Analysis of the data showed that the sensation of persistent reduction in taste was 
significantly associated with the time since transplantation, with progressively less 
subjects complaining of moderate to severe dysgeusia as this time increased (P=0.031). 
Dysgeusia was also related with transplant type, PBSCT showed a significantly higher 
proportion of subjects with a complaint of reduced taste (P=0.045). Of note, a history of 
TBI and myeloablative therapy was not associated with reduced taste. Both xerostomia 
and dysgeusia were significantly associated with the frequency of dental reviews after 
HSCT with the number of subjects with xerostomia increasing as dental reviews 
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became less frequent (P=0.029). Interestingly, the number of subjects who reported an 
accelerated decay rate post-HSCT was not associated with TBI, myeloablative therapy, 
time since HSCT or whether they had a dental examination prior to transplantation. 
 
4.3.4 Results for the objective complications after transplantation 
The objective parameters which were investigated, representative of the clinical 
spectrum of oral cGVHD, included maximal oral opening (millimetres), stimulated 
saliva (over a 5 minutes period), presence of mucosal oral cGVHD and candidosis.
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Chart 4.3.4: Percentage of subjects with objective oral complications after 
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4.3.4.1 Analysis of salivary hypofunction 
A reduction in stimulated saliva was the most common objective feature of oral 
cGVHD, with 34.1% of subjects demonstrating some degree of hypofunction. Severe 
salivary hypofunction, measured as less than 3.5ml of stimulated saliva over 5 minutes, 
was seen in 19.3% of subjects (Chart 4.3.4.1). A significant association was seen 
between the time since transplantation and the degree of salivary hypofunction 
(P=0.023). Only 44.4% of subjects at 6 months to 2 years after HSCT demonstrated 
normal (>5ml) stimulated saliva quantities compared to 80% (n=16) of subjects 2 to 3 
years after transplantation (Table 4.3.4.1). A clear trend was also visible between the 
presence of aGVHD and the severity of salivary hypofunction (P=0.067). Subjects with 
a pre-existing history of aGVHD displayed greater salivary hypofunction in general 
(53.1% versus 22.2%) and a higher proportion of severe hypofunction (27.5% versus 
8.3%). Candidosis was present on visual inspection in 11.4% of subjects. 
Table 4.3.4.1: Stimulated saliva (ml) relative to time since HSCT 
  Stimulated Saliva (5min)  
  
  
>5ml 3.5-5ml <3.5ml Total 
Time since 
HSCT 
6mo-
2yrs 
Count 12 3 12 27 
    % within this 
time  
44.4% 11.1% 44.4% 100.0% 
  2-3yrs Count 16 3 1 20 
    % within this 
time  
80.0% 15.0% 5.0% 100.0% 
  3-4yrs Count 14 2 3 19 
    % within this 
time  
73.7% 10.5% 15.8% 100.0% 
  4-5yrs Count 9 4 1 14 
    % within this 
time  
64.3% 28.6% 7.1% 100.0% 
  5-6yrs Count 7 1 0 8 
    % within this 
time  
87.5% 12.5% .0% 100.0% 
Total Count 58 13 17 88 
  % within Time  65.9% 14.8% 19.3% 100.0% 
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4.3.4.2 Analysis of mucosal oral chronic graft-versus-host disease 
Mucosal oral cGVHD was seen in 20.5% of subjects, most commonly involving the 
buccal mucosa (88.9%) followed by the lateral tongue (44.4%) and gingiva (5.6%). 
Lesions generally presented bilaterally (77.8%). The pattern of presentation of oral 
mucosal cGVHD was generally reticular (66.7%) or plaque-like (38.9%) (Figure 
4.3.4.2), ulcerative and atrophic areas were noted (27.8% and 5.6% respectively). More 
than one clinical pattern of mucosal oral cGVHD was seen in 38.9% of subjects at the 
time of examination. The likelihood of developing oral mucosal cGVHD was strongly 
associated with stem cell source (P=0.051), with all those with oral mucosal cGVHD 
having received PBSCT (n=18). Subjects who had received TBI displayed a clear trend 
for being free of oral mucosal cGVHD involvement (P=0.051), with 9.4% (n=3) of 
subjects who had received TBI developing lichenoid lesions relative to 26.8% (n=15) 
who had not received TBI. Of interest, when analysing the risk factors for the 
development of mucosal oral cGVHD there was no significant association with a 
history of aGVHD, mucositis, type of conditioning regimen, donor type and time since 
transplantation. This was in stark contrast to the findings for the overall risk of 
developing oral and cGVHD which were both strongly associated with aGVHD. 
Figure 4.3.4.2: Presentation of oral mucosal cGVHD in two subjects. (A) Plaque-like mucosal lesion           
(B) Reticular cGVHD with ulceration 
A B 
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4.3.4.3 Analysis of maximal oral aperture 
In 42.1% of subjects the maximum unassisted oral opening was reduced below the 
normal range reported for healthy adults. In 15 subjects (17.1%) oral aperture was less 
than 39mm (measured interincisally), placing them in a moderate to severe category. Of 
note, the presence of reduced oral opening was not found to be associated with; age at 
transplantation, history of aGVHD, TBI, stem cell source or conditioning regimen. 
 
4.4 Pre-transplant education 
The majority of subjects had a pre-transplant dental exam however a significant 
proportion (20.5%) did not. When asked about the frequency of their dental attendance 
prior to HSCT, most subjects stated they did not see a dentist regularly with over 1 year 
between visits. This pattern of attendance did not alter significantly after 
transplantation; the majority of subjects still recorded infrequent dental reviews (>1 
year). Of the subjects who did not see a dentist regularly (>1 year between visits) 56.8% 
(n=25) were unaware of the need to seek regular dental reviews after HSCT while 
18.2% were impeded by the cost involved. Over half of the subjects were aware that 
long-term oral complications could arise after HSCT (56.8%) however a significant 
number were unable to recall (15.9%) and 27.3% were not aware of these potential 
complications. The most useful education source pertaining to the oral outcomes of 
transplant was identified as the transplant physician (19.3%). Other valuable sources 
included the BMTU Education Day (15.9%) and the education book circulated by the 
BMTU in the pre-transplant phase. Only 18.2% of subjects reported that they did not 
receive enough information. Although most subjects‟ favoured pre-transplant delivery 
of information, a significant proportion preferred that this information be given at their 
first outpatient review (18.2%) or a combination of both (22.7%).  
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Chapter 5: DISCUSSION 
 
Haematopoietic stem cell transplantation is now an established therapy for a range of 
haematological malignancies, conditions associated with marrow failure, immune 
deficiencies and some solid tumours however, effective therapy is associated with high 
mortality and morbidity. A range of oral complications may be seen following 
allogeneic HSCT which include mucosal cGVHD, salivary hypofunction, peri-oral 
fibrosis and second malignancies. Unfortunately the incidence of oral complications 
after allogeneic HSCT and the association with preparatory regimens and other factors 
has not been clearly elucidated. This study was designed to investigate the incidence 
and risk factors for the development of oral long-term complications following 
allogeneic HSCT. 
 
The study population consisted of 88 patients who underwent allogeneic HSCT at a 
major Australian transplant unit (Westmead Hospital BMTU). The vast majority of 
these patients received PBSCT (79.5%) where AML was the most common underlying 
diagnosis preceding transplantation (55.7%) followed by NHL (14.8%) (Table 5.1). The 
population characteristics were consistent with the most recently published data from 
the ABMTRR and EBMTR. 
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Table 5.1: Proportion of allogeneic transplants for major indicators 
 Indicator as a proportion of total allografts 
Indicator   ABMTRR EBMT Study population 
AML 43% 32% 55.7% 
ALL 19% 19% 12.5% 
CML 8% 11% Nil 
NHL 9% 7% 14.8% 
 
The long-term oral complications following allogeneic HSCT comprise of a significant 
clinical spectrum. Conditions identified as diagnostic presentations of oral cGVHD by 
the NIH consensus project (2005) include oral mucosal cGVHD, salivary hypofunction 
and sclerodermatous-like fibrosis of the peri-oral tissues. Other, associated lesions 
include mucoceles, candidosis and the development of pseudomembranes (Filipovich, 
Weisdorf et al. 2005). This study assessed the range and frequency of the dental/oral 
long-term complications in a cohort of patients who received allogeneic HSCT at the 
Westmead Hospital BMTU. Chronic GVHD arose in 72% of subjects after 
transplantation with 56% of subjects having some form of oral involvement. The 
development of oral cGVHD was significantly associated with a preceding history of 
aGVHD however the presence of oral cGVHD was not significantly influenced by a 
history of mucositis, the age at transplantation, donor type, transplant type or the 
conditioning regimen used.  
 
Salivary hypofunction was the most common oral sign of cGVHD with 34% of subjects 
demonstrating some degree of involvement. Mucosal oral cGVHD was also relatively 
prevalent in this population with 20.5% of subjects showing clinical evidence of 
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lichenoid changes. Presumed peri-oral fibrosis, clinically presenting as reduced oral 
aperture, was present to a significant degree in 17% of subjects. Candidosis was not 
seen frequently in this subject group with only 11% of subjects demonstrating evidence 
of candidosis on visual inspection with angular chelitis and denture-associated 
stomatitis being the most common forms. Due to the small number of subjects 
displaying features of candidosis at the time of examination, it was not possible to 
convincingly establish whether the presence of candidosis was a primary complication 
of cGVHD or secondary to features of transplantation such as current 
immunosuppression or salivary hypofunction. 
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Acute complications 
Mucositis 
Mucositis is a common acute toxicity related to both chemotherapy and on occasion the 
use of TBI associated with the conditioning regimen for allogeneic transplantation and 
can be the most distressing acute toxicity for patients (Bellm, Epstein et al. 2000). The 
literature suggests that 75-99% of patients receiving myeloablative conditioning 
regimens will develop some degree of mucositis (Donnelly, Muus et al. 1992). In this 
study population, when the information pertaining to the presence of mucositis was 
available (n=69), some 70% of subjects developed some degree of mucositis. A 
statistically significant correlation was seen between the risk for mucositis and its 
severity with the use of a myeloablative conditioning regimen (P<0.001). In subjects 
who received myeloablative conditioning therapy (n=41) 87.8% developed mucositis 
relative to only 42.9% of subjects who received RIC. As expected, myeloablative 
conditioning regimens, including the combinations of busulphan-cyclophosphamide and 
cyclophosphamide-TBI, were identified as predicting a high risk for mucositis. These 
conditioning regimens were also significantly associated with a predisposition for grade 
3-4 mucositis (WHO 1979) (53.8% and 47.4% respectively) in stark contrast to subjects 
receiving melphan based therapy, with no subject developing grade 3-4 mucositis. 
Subjects who received TBI almost always developed mucositis with 92.3% of subjects 
affected in contrast to 55.8% of subjects who did not receive TBI. 
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Acute graft-versus-host disease 
The intensity of the preparative regimen has also been shown to correlate with the 
development of aGVHD with patients receiving myeloablative conditioning regimens at 
a higher risk of developing aGVHD. This effect is thought to be associated with the 
significant tissue damage caused by myeloablative preparative regimens which 
predispose the tissues to more inflammation from the alloreactive cells (Jacobsohn and 
Vogelsang 2007). The incidence of aGVHD has been reported as effecting between 
35%-50% of allogeneic transplant patients (Jacobsohn and Vogelsang 2007). The most 
significant risk factors identified in the literature for the development of aGVHD are the 
degree of HLA mismatch, use of a MUD, myeloablative conditioning regimens and 
high dose irradiation (Beatty, Clift et al. 1985). This is attributed to the degree of 
epithelial damage associated with these therapies (Hill and Ferrara 2000). The data 
gathered on this set of subjects confirms these associations. Over half of subjects 
developed aGVHD (59%) with the use of myeloablative regimens, TBI and MUD being 
significantly associated with development of aGVHD. Conversely, some authors have 
postulated that RIC would be associated with a lower incidence and less severe aGVHD 
due to the reduction in treatment related mucosal toxicity (Epstein, Raber-Drulacher et 
al. 2009). This supposition was not supported in this study population. Although 
subjects who received RIC displayed a significantly lower incidence of aGVHD 
(P=0.024) there was surprisingly not a significant difference in the severity of aGVHD 
in subjects who received myeloablative or RIC regimens (P=0.684). 
 
The literature highlights considerable changes in the clinical picture and natural history 
of aGVHD over the recent years which are attributed to the numerous advances in 
HSCT practice. Traditionally, clinical evidence of GVHD prior to 100 days post-
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transplantation was presumed to be aGVHD however this is no longer definite. A clear 
distinction between acute and chronic GVHD, based on the time of occurrence alone, is 
no longer feasible and diagnosis should rely on the unique clinical and histological 
features to distinguish between these conditions. As such, the NIH classification system 
has recently been published with clear changes to the classification and diagnosis of 
both acute and chronic GVHD to acknowledge these developments (Filipovich, 
Weisdorf et al. 2005). RIC is one factor which has been suggested as changing the 
natural history of aGVHD, with patients presenting with features unique for aGVHD, 
such as maculopapular rash, profuse diarrhoea, or cholestatic hepatitis (Filipovich, 
Weisdorf et al. 2005), more than 100 days after transplantation (Mielcarek, Martin et al. 
2003). In this patient population the majority of subjects who developed features of 
aGVHD did so within the first 100 days (86.5%) however 13.5% of subjects were 
diagnosed with aGVHD beyond 100 days post-transplantation.  
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Chronic complications 
Chronic GVHD remains the leading cause of non-malignancy related fatality post 
allogeneic HSCT (Ferrara and Reddy 2006) accounting for approximately one quarter 
of deaths in long term survivors of HSCT for leukaemia (Ratanatharathorn, Ayash et al. 
2001). A reliable estimate of the incidence of cGVHD is hindered by the lack of 
standardised diagnostic guidelines but the literature reports that between 25-80% of 
patients receiving allogeneic transplantation will develop cGVHD (Baird and Pavletic 
2006). Known risk factors consistently associated with cGVHD include the use of 
PBSCT, increasing age of the patient, a matched unrelated donor, TBI and a preceding 
history of aGVHD (Cutler, Giri et al. 2001; Lee 2005; Baird and Pavletic 2006). 
 
Chronic graft-versus-host disease 
In the cohort of subjects studied cGVHD arose in 64 of 88 subjects (72.7%) with the 
time of onset primarily within the first 3-12 months after HSCT. Acute GVHD was a 
significant risk factor for the development of cGVHD in this population with 69.8% of 
subjects who developed cGVHD having a preceding diagnosis of aGVHD in contrast to 
the 30.2% of subjects with cGVHD who did not have aGVHD (P=0.001). The 
probability of developing cGVHD has also been linked to the grade of aGVHD. 
Patients who develop grade 2-4 aGVHD have been shown to be more likely to develop 
cGVHD (Ratanatharathorn, Ayash et al. 2001). This was not replicated in this study 
population however, since information pertaining to the severity of aGVHD was only 
recorded for 73% of subjects it is unclear if we have captured an accurate assessment of 
the proportion of subjects who developed grade 1-2 versus grade 3-4 aGVHD. No other 
risk factors predicted the onset of cGVHD including PBSCT, increasing age, MUD and 
TBI. It is possible that these associations were not evident due to the small subject pool. 
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 Oral long-term complications of transplantation 
The oral cavity is frequently involved in the spectrum of cGVHD, the literature 
suggesting that between 72% to 83% of patients diagnosed with cGVHD demonstrate 
some degree of oral involvement (Schubert and Correa 2008). The incidence of oral 
cGVHD was somewhat reduced in this study population with only 56.3% of subjects 
diagnosed with cGVHD demonstrating oral features of cGVHD. However the oral 
cavity was still one of the most commonly affected sites in cGVHD with 56.3% of 
subjects with cGVHD showing oral involvement, second only to the skin (70.3%).  
 
This discrepancy in the prevalence of oral involvement in subjects diagnosed with 
cGVHD may be partially attributable to the way in which this information was attained. 
In each patient the history of cGVHD is unique including; time of onset, organs 
involved and the duration of active disease. In order to capture a true incidence of 
cGVHD in this study population the medical records of each subject was assessed by 
the researcher for any documentation, at all outpatient reviews since transplantation, of 
oral cGVHD. It was thought that this method of assessing disease incidence would 
more accurately capture all subjects who developed oral cGVHD at some point 
following transplantation. So, the overall number of subjects affected by oral cGVHD 
was not based on the findings of the Participant Examination Form. This examination 
allowed only an isolated appraisal of each subject‟s complex and prolonged post-
transplantation disease history and therefore was thought to not accurately represent 
disease incidence. Throughout the post-transplant period several transplant physicians 
and haematology registrars were involved in each subject‟s review and the 
documentation of clinical findings. Clearly, examination techniques vary between all 
clinicians and due to the lack of availability of a standardised approach for the 
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assessment of the oral cavity it is possible that documentation of oral involvement may 
have been either over, or more probably, under-diagnosed.  
 
Risk factors identified for the development of oral cGVHD 
The risk factors specific for the development of oral cGVHD remain largely unknown 
however, recent studies have suggested an association with transplant type; a higher 
degree of oral involvement (70%) seen in PBSCT relative to BMT (53%) (Pavletic S. Z, 
Smith L.M et al. 2005). This trend was replicated in this group of subjects where those 
treated with PBSCT showed the highest degree of oral cGVHD (44.3%) relative to 
BMT (28.6%) and UC transplantation (25%). However, due to the very small numbers 
of patients receiving umbilical cord transplants during the study period (n=4) it is 
unlikely that a true representation of this group is possible. Other associations seen in 
this group of subjects included a past history of aGVHD (P=0.015) and the presence of 
cutaneous, hepatic or ocular cGVHD. No other statistically significant risk factors were 
identified including mucositis, TBI, myeloablative conditioning or MUD.  
 
Mucosal oral cGVHD 
Oral cGVHD closely resembles, both clinically and histologically, other autoimmune 
disorders including scleroderma and Sjögren syndrome and the immune-mediated 
condition lichen planus. Oral mucosal lesions of cGVHD present, most commonly, as 
lichenoid lesions which typically arise as fixed, fine white striations and hyperkeratotic 
plaques. Although almost any oral site may be involved, the sites most commonly 
reported include the buccal mucosa, tongue and labial mucosa (Treister, Woo et al. 
2005). In the sample of patients studied, mucosal oral cGVHD lesions were seen in 
20.5% of subjects at the time of examination. The sites involved were consistent with 
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those reported in the literature with the vast majority of subjects showing involvement 
of the buccal mucosa (88.9%) followed by the lateral tongue (44.4%) and gingiva 
(5.6%). Mucosal lesions generally existed bilaterally with reticular lesions (66.7%) and 
plaque-like areas (38.9%) representing the most common pattern of presentation.  
 
Statistically significant risk factors identified for the development of oral mucosal 
cGVHD were limited in number. A clear association was seen between the prevalence 
of oral mucosal cGVHD and the type of transplant, with all subjects who developed 
mucosal cGVHD having received PBSCT (n=18).  This is in keeping with the known 
association of an increased risk of developing cGVHD in patients receiving PBSCT 
(Stem Cell Trialists' Collaborative Group 2005). However it is unlikely that the 
distribution of oral mucosal cGVHD relative to transplant type is justly represented in 
this sample due to the significantly inferior number of BMT and UC transplants in this 
group relative to PBSCT. Furthermore, it is difficult to know that if by clinically 
examining every subject once only allows a true representative assessment of this 
group. In this study, when analysing the risk factors for oral mucosal cGVHD alone, 
there was no significant association with aGVHD, mucositis, conditioning regimen, 
MUD and time since transplantation. The lack of association with aGVHD was in stark 
contrast to the strong association identified for developing chronic GVHD and oral 
cGVHD in general. 
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Salivary hypofunction 
Acute post allogeneic HSCT salivary gland dysfunction is predominantly attributed to 
conditioning regimen toxicity, especially in the case of TBI, and can persist for many 
months. Late changes are most often ascribed to cGVHD and clinically resemble the 
features of Sjögren syndrome (Coracin, Pizzigatti Correa et al. 2006). Extensive 
involvement results in the total destruction of secretory units leading to permanent and 
profound salivary hypofunction (Schubert and Izutsu 1987). The most prominent risk 
factor in the aetiopathogenesis of salivary cGVHD, which has been implicated 
extensively in the literature, is TBI (Hemidahl, Johnson et al. 1985). Other confounding 
factors when assessing the cause of salivary hypofunction in these subjects include 
radiotherapy to the head and neck region and the polytherapy often required in the 
management of these patients following transplantation.  
 
The reduction in salivary flow has been reported in 55 to 90% of patients diagnosed 
with cGVHD with the severity of hypofunction being proportional to the severity of 
systemic cGVHD (Schubert, Sullivan et al. 1984). In this group of subjects reduced 
stimulated salivary flow, measured over 5 minutes, was the most consistent, objectively 
measured, adverse effect with 34% demonstrating some degree of hypofunction. Severe 
hypofunction, measured as <3.5ml over 5 minutes, was seen in 19% of subjects. The 
prevalence of salivary hypofunction in this study population is clearly lower than that 
previously reported however Schubert el al utilised visual assessment only when 
documenting salivary hypofunction. Clearly, the use of different tools to diagnose 
salivary hypofunction in this study would explain the divergence in results. A 
significant inverse association was seen between the time elapsed since transplantation 
and the prevalence of salivary hypofunction (P=0.023) with only 44.4% of subjects 6 
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months to 2 years after HSCT having normal (>5ml) stimulated saliva quantities 
compared to 80% of subjects 2-3 years post transplant. This trend may not only reflect 
salivary cGVHD but may be prejudiced by the proximity of the time since TBI delivery 
and the intense conditioning regimens delivered during the early phases of 
transplantation. Salivary tissue is extremely radiosensitive however some degree of 
recovery is possible with time, which may explain the strong improvement in salivary 
function as the time since transplantation increases. An interesting correlation was also 
visible between the previous diagnosis of aGVHD and the severity of salivary 
hypofunction (P=0.067) with subjects who had a history of aGVHD having a higher 
proportion of severe hypofunction (27.5% versus 8%). Salivary hypofunction, in this 
study population, was not significantly associated with a history of TBI (P=0.513). 
 
The literature shows oral dryness as the second most distressing symptom recorded by 
patients at discharge and at 1 year following HSCT (Larsen, Nordstom et al. 2007). 
Xerostomia, the subjective complaint of oral dryness, is by definition irrespective of the 
clinical signs of salivary hypofunction and is commonly reported in patients with 
clinically normal salivary function. In this study, xerostomia was reported in 44% of 
subjects (n=39) with 43.6% (n=17) of these subjects grading their degree of xerostomia 
as moderate to severe. Interestingly, in this group of subjects, a sensation of oral 
dryness was not statistically associated with a history of TBI and that the risk factors 
identified for clinically evident salivary hypofunction were not transferable to subjects 
who self reported a sensation of oral dryness (xerostomia). Specifically, the time since 
transplantation did not predict the prevalence of xerostomia (P=0.461) and a history of 
aGVHD did not preclude the complaint of oral dryness (P=0.740). Interestingly, only 
13 subjects thought these factors impacted on their quality of life. 
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Previous authors have reported that often the symptom of xerostomia does not correlate 
with the objective clinical signs of salivary hypofunction; where clinical features may 
demonstrate a reduction in salivary flow in patients who do not complain of a dry 
mouth (Alborghetti M.R, Correa M.E et al. 2005). When the subjects who clinically 
demonstrated reduced salivary flow (stimulated saliva <5ml over 5 minutes) were 
compared to the subjects who self-reported a sensation of oral dryness (xerostomia) a 
measurement of agreement value of 0.288 (ideally 1.0) was obtained, demonstrating 
poor overlap between these subjects. For example, only 10 subjects of the 17 who were 
categorised as having severe salivary hypofunction on examination (<3.5ml) also self-
reported a sensation of moderate to severe xerostomia (Table 5.2). Conversely, during 
clinical examination, 6 subjects who self-reported a sensation of severe xerostomia 
actually demonstrated normal salivary function during the clinical examination (>5ml). 
This is in agreement with the findings of other authors who suggested that the symptom 
of xerostomia does not necessarily correlate with clinical evidence of salivary 
hypofunction. Furthermore, this would suggest that in everyday clinical practice, basing 
our diagnosis of cGVHD salivary involvement on a patient‟s self-reported sensation of 
xerostomia is not an accurate indication of this feature. 
 
Table 5.2: Analysis of agreement of the subjective and objective diagnosis of oral dryness 
 
Stimulated Saliva (5min) 
Total >5ml 3.5-5ml <3.5ml 
Xerostomia None 39 8 2 49 
Mild 13 4 5 22 
Mod-Severe 6 1 10 17 
Total 58 13 17 88 
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Dysgeusia 
Altered taste sensation (dysgeusia) is a common conditioning regimen-related 
phenomenon which typically resolves 1 to 2 months following HSCT (Comeau, Epstein 
et al. 2001). Late dysgeusia and/or hypogeusia (reduced taste) or ageuisa (absence of 
taste) can persist or arise in the later stages following HSCT and is often coupled with 
the onset of cGVHD. Also, a reduction in the quantity of saliva seen in cGVHD 
involving the salivary glands, may further promote an altered taste perception due to the 
reduced capacity for saliva to act as a solvent. In this study population, the complaint of 
altered or reduced taste more accurately predicted the subjects with clinically reduced 
salivary function (P<0.001). All subjects who recorded severe taste disturbances (n=3) 
clinically demonstrated severe salivary hypofunction. Conversely, 72.9% (n=51) of 
subjects which did not record any disturbance in their sensation of taste clinically 
demonstrated normal salivary function. Subjects who reported only a mild disturbance 
in taste did not accurately reflect true mild salivary hypofunction. Approximately half 
of these subjects demonstrated normal salivary flow and the remainder had more severe 
hypofunction than predicted (Table 5.3). This information would suggest that in our 
clinical practice, questions pertaining to changes in taste may be a more accurate 
predictor of true salivary hypofunction compared to a patient‟s subjective reporting of 
oral dryness. 
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Table 5.3: Correlation of the complaint of altered taste with salivary function 
 
Stimulated Saliva (5min) 
Total 
>5ml 3.5-5ml <3.5ml 
Taste None Count 51 12 7 70 
% within Taste 72.9% 17.1% 10.0% 100.0% 
Mild Count 7 1 7 15 
% within Taste 46.7% 6.7% 46.7% 100.0% 
Mod-Severe Count 0 0 3 3 
% within Taste .0% .0% 100.0% 100.0% 
Total Count 58 13 17 88 
% within Taste 65.9% 14.8% 19.3% 100.0% 
 
 
Analysis of the data showed that the subjective sensation of a persistent reduction in 
taste was also significantly inversely associated with the time since transplantation, with 
progressively less subjects complaining of moderate to severe dysgeusia as the time 
since transplantation increased (P=0.031). Of note, a history of TBI and myeloablative 
therapy was not associated with a reduced taste.  
111 
 
Alterations in maximal oral aperture 
Sclerodermatous changes in the perioral tissues, in patients with cutaneous cGVHD,  
may result in a reduced oral aperture (da Fonseca, Schubert et al. 1998) potentially 
hindering the provision of dental care and the maintenance of oral hygiene. This 
perioral fibrosis and restricted oral range of motion resembles, both clinically and 
histologically, that seen in scleroderma (Imanguli, Alevizos et al. 2008). These clinical 
measurements allowed each subject to be categorised relative to their degree of oral 
opening. Normal oral aperture was taken as any measurement higher than, and inclusive 
of 50 millimetres (mm). The literature shows that the mean maximal unassisted opening 
falls in the range of 50mm to 60mm in normal, healthy adults (Posselt 1962; Dworkin 
and LeResche 1992). The maximal oral aperture (measured interincisally) was reduced 
in 42% of subjects with 17% (n=15) of subjects demonstrating moderate to severe 
reductions in opening (interincisal distance ranging from 39mm to 23mm). Of note, one 
of the subjects in this group, who measured a maximum of opening of 39mm, had a pre-
existing diagnosis of scleroderma prior to transplantation.  
 
Interestingly, when each subject was questioned about their perception of a reduced oral 
opening since transplantation, only 4 subjects (4.5%) complained of moderate to severe 
reduction. This was in stark difference to the number of subjects (n=15) who 
demonstrated clinical evidence of oral opening less than the normal range. Furthermore 
when these two groups of subjects were compared, 8 subjects of the 15 who clinically 
demonstrated reduced oral aperture self-reported their opening as normal. However, 
several clear confounding factors hinder the usability of this data. Numerous alternate 
causes for a reduced maximal oral opening are possible, some of the most noteworthy 
being myalgia of the muscles of mastication, arthralgia of the temporomandibular joint 
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and a pre-existing diagnosis of autoimmune scleroderma. Subjects were questioned on 
confounding factors such as true scleroderma however a complete temporomandibular 
examination was beyond the scope of this study and so cannot be excluded as a 
potential confounder in this group of subjects.  
 
Lastly, this study was retrospective in design; subjects were not examined prior to 
transplantation. Ideally, if subjects were examined prior to the onset of the 
transplantation process obviously a more accurate assessment of changes in oral 
opening would have been possible. Without a baseline recording pre-transplant it is 
impossible to accurately predict which subjects showed a true reduction in oral aperture 
as a consequence of sclerodermatous cGVHD involving the peri-oral tissues.  
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Second malignancies 
The development of new second malignant neoplasms and lymphoproliferative 
disorders following HSCT has long been recognised as an uncommon but significant 
complication for long-term survivors of HSCT (Demarosi, Lodi et al. 2005), patients 
having a 13-fold higher risk for developing second malignancies, including leukaemias, 
lymphoproliferative disorders and solid tumours (Curtis, Rowlings et al. 1997). In the 
early post-transplant period, with a peak in the first 2 years, lymphoproliferative 
disorders and haematologic malignancies predominate as the most common second 
malignancies. More commonly involving the oral cavity, solid tumours may develop 
many years following HSCT with their incidence continuing to rise over the years 
following transplantation, the most common malignancy involving the oral cavity being 
SCC (Epstein, Raber-Drulacher et al. 2009). The median time from HSCT to solid 
tumour diagnosis has been shown to be 7 years ( 0.9 to 22 years) with a cumulative 
incidence of 1.1% at 20 years (Curtis, Metayer et al. 2005). Within the oral cavity the 
tongue, buccal mucosa, gingiva and lip are most frequently involved (Abdelsayed, 
Sumner et al. 2002). The literature also shows the development of solid malignancies at 
sites previously or concurrently affected with GVHD (Abdelsayed, Sumner et al. 2002).  
 
In this subject pool no solid malignancies of the oral cavity were diagnosed. Subjects in 
this study ranged from 6 months to 6 years post allogeneic HSCT. The majority 
(53.4%) in the period of 6 months to 3 years post transplantation with only 9.1% being 
5 to 6 years post transplantation. So, it is clear that although all subjects were beyond 
the immediate post transplant phase, the majority of subjects had not progressed 
sufficiently in regards to duration post transplantation to accurately assess the incidence 
of certain long term complications such as the development of solid malignancies.
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Pre-transplant education 
The last section of this project examined transplant recipients‟ views concerning the 
adequacy of pre-transplant education in reference to the long-term oral complications of 
HSCT, the optimal time for the delivery of information about oral health and the overall 
compliance with pre-transplant dental assessment. This data was hoped to allow for 
future adjustment of educational methods to align with overall patient need.  
 
Patients planned for allogeneic HSCT are encouraged to seek a dental assessment prior 
to the commencement of the transplantation process. This assessment is either 
completed by the patient‟s own general dentist or an examination is arranged with an 
Oral Medicine Specialist within Westmead Hospital BMTU. The majority of subjects in 
this study did have a pre-transplant dental assessment however a significant proportion 
(20.5%) did not. When asked about the frequency of their dental attendance prior to 
transplantation most subjects stated that they did not see a dentist regularly with over 1 
year between visits. This pattern of attendance did not alter significantly after 
transplantation; the majority of subjects still recorded infrequent dental reviews (>1 
year). Of the subjects which did not see a dentist regularly (>1 year between visits) 49% 
were unaware of the need to seek regular dental reviews while 9.8% did not seek 
regular dental care due to the cost involved.  
 
Regular dental assessment following allogeneic transplantation is an essential 
component of outpatient care. As evident by this study, the oral cavity is a frequently 
involved site in the spectrum of cGVHD with 56.3% of subjects diagnosed with 
cGVHD demonstrating some degree of oral involvement making the oral cavity the 
second most common site affected by cGVHD. The oral manifestations of cGVHD are 
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varied and numerous and can include lichenoid lesions, salivary hypofunction, peri-oral 
fibrosis and second malignancies involving the oral cavity. The role of the Oral 
Medicine Specialist and general dentist is therefore crucial for the assessment and 
monitoring of these outcomes and for the management of the complex dental needs of 
these patients. In this subject group over half of the subjects were aware that long-term 
oral complications could occur after transplantation (57%) however a significant 
proportion were unable to recall (16%) or were not aware of these complications (27%). 
The most useful source of information pertaining to the oral complications of transplant 
was identified as the transplant physician (19.3%). Other valuable sources included the 
BMTU Education Day (16%) and the education book circulated by the BMTU. 
Although most participants favoured pre-transplant delivery of this information, a 
significant proportion preferred that this information be given at their first outpatient 
review appointment (18%) or both pre and post transplantation (22.7%).  This finding 
may suggest that the second delivery of information at outpatient review, specific to the 
long-term oral complications post transplantation, may be well received.  
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Limitations of this study 
This project was a retrospective analysis of the long-term oral complications faced by a 
series of subjects who received allogeneic HSCT at the Westmead Hospital BMTU. 
The retrospective nature of this study made it difficult to truly assess the extent of some 
oral complications seen after transplantation; such as reduced oral aperture, salivary 
hypofunction and decay rate. Without a pre-treatment, baseline assessment it is difficult 
to uniformly state that the complications that were recorded were purely as a result of 
the transplantation procedure. Although subjects were questioned about the most 
frequent confounding factors like a prior diagnosis of Sjögren syndrome, oral lichen 
planus, scleroderma or previous head and neck radiotherapy, there is no clear method to 
exclude the subjects who may have displayed these oral changes prior to transplantation 
due to other causes. 
 
Due to the considerable number of deaths within the initial cohort of patients who 
received HSCT within the designated time period and the substantial number of 
subjects who declined participation, there remains the possibility of selection bias. The 
characteristics of the non-participants may have been dissimilar to the final study 
population. This factor may have influenced the reported incidence of oral cGVHD and 
associated risk factors in this group.   
 
Lastly, in this study the diagnosis of the majority of oral complications in the spectrum 
of oral cGVHD was completed using clinical tools only. Without histological analysis, 
subjects clinically displaying features of lichenoid cGVHD or reduced salivary capacity 
cannot be, without doubt, diagnosed with cGVHD. In the ideal setting these clinical 
diagnoses would be confirmed with histopathological analysis. 
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Implications of research and future directions 
The aim of this study was to assess the extent and range of the long-term oral 
complications which can occur following allogeneic transplantation. From this data set, 
it can be seen that this clinical spectrum includes lichenoid-like mucosal lesions, 
salivary hypofunction, peri-oral fibrosis and altered taste sensation. For a minority of 
patients these oral manifestations impact on their quality of life post-transplantation. 
This study has identified a select number of risk factors which seem to be significantly 
associated with the development of cGVHD and specifically oral cGVHD. The most 
prominent risk factor identified for the development of oral involvement within the 
cGVHD spectrum included a past history of aGVHD (P=0.015). Subjects were also 
more likely to develop oral cGVHD with a history of cutaneous, hepatic or ocular 
cGVHD. Significantly, no other risk factors were identified; mucositis, TBI, 
myeloablative conditioning or MUD did not significantly predict the risk for oral 
cGVHD. With so few predictive factors known, this data highlights the unique 
difficulties faced when diagnosing and managing these patients.  
 
The second aspect to this study was to assess the adequacy of education material for the 
long-term oral complications of allogeneic HSCT. The vast majority of subjects were 
aware of the potential oral complications that could arise however a strong proportion 
of subjects agreed that delivery of this information may be more useful in the outpatient 
setting or both pre and post transplantation. Ideally this data may be used to aid in 
tailoring future education material to further address patient needs.  
 
Several new research directions may follow on from this preliminary work. Analysis of 
the histology of the clinical lesions and complications diagnosed in these subjects, via 
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incisional biopsy, would allow for more accurate diagnosis and a further understanding 
of the pathophysiology and natural history of these complications. Through this 
research it was clear that many subjects were not able to find successful and easily 
accessible management strategies for the oral complications experienced after 
transplantation. Further research could focus on developing patient education pamphlets 
which would help patients understand their oral changes and offer simple and accessible 
management strategies. 
 
In conclusion, it is evident that oral long-term complications are a common occurrence 
following allogeneic haematopoietic stem cell transplantation with over half of the 
patients (56.3%) who developed cGVHD having some form of oral involvement. The 
most common clinical presentations were of salivary hypofunction and mucosal oral 
cGVHD. Although the majority of subjects did report receiving adequate information 
regarding these potential oral complications, a significant proportion of this study 
population showed interest in attaining further education and more detailed 
management strategies in the outpatient setting. This study has clearly shown that oral 
complications after transplantation are common and require regular review and 
appropriate management as part of the routine outpatient assessment of all 
haematopoietic stem cells transplant patients. 
 
 
119 
 
REFERENCES 
 
Abdelsayed, R. A., T. Sumner, et al. (2002). "Oral precancerous and malignant lesions 
associated with graft-versus-host disease: Report of 2 cases." Oral Surgery, Oral 
Medicine, Oral Pathology, Oral Radiology and Endodontics 93: 75-80. 
Agha-Hosseini, F., I. Mirzaii-Dizhag, et al. (2007). "Effect of pilocarpine hydrochloride on 
unstimulated whole saliva flow rate and composition in patients with chronic graft-
versus-host disease." Bone Marrow Transplantation 39: 431-434. 
Al-Hashimi, I., M. Schifter, et al. (2007). "Oral lichen planus and oral lichenoid lesions: 
diagnostic and therapeutic considerations." Oral Surgery, Oral Medicine, Oral 
Pathology, Oral Radiology and Endodontics 103 (suppl 1): e1-e11. 
Alborghetti M.R, Correa M.E, et al. (2005). "Late effects of chronic graft-versus-host disease in 
minor salivary glands." Journal of Oral Pathology and Medicine 34: 486-493. 
Anasetti, C., D. Amos, et al. (1989). "Effect of HLA compatibility on engraftment of bone 
marrow transplants in patients with leukaemia or lymphoma." The New England 
Journal of Medicine 320: 197-204. 
Andrews, M. L., I. Robertson, et al. (1997). "Cutaneous manifestations of chronic graft-versus-
host disease." Australasian Journal of Dermatology 38: 53-62. 
Aractingi, S. and O. Chosidow (1998). "Cutaneous graft-versus-host disease." Arch Dermatol 
134: 602-612. 
Bagger, Y. Z., L. B. Tanko, et al. (2003). "Aledronate has a residual effect on bone mass in 
postmenopausal Danish women up to  7 years after treatment withdrawal." Bone 33: 
301-307. 
Baird, K. and S. Z. Pavletic (2006). "Chronic graft versus host disease." Current Opinion in 
Hematology 13(6): 426-35. 
Bamias, A., E. Kastritis, et al. (2005). "Osteonecrosis of the jaw in cancer after treatment with 
bisphosphonates: incidence and risk factors." Journal of Clinical Oncology 23: 8580-
8587. 
Barnes, D., M. Corp, et al. (1956). "Treatment of murine leukaemia with x-rays and 
homologous bone marrow: Preliminary communication." British Medical Journal 2: 
626. 
Beatty, P. G., R. A. Clift, et al. (1985). "Marrow transplantation from related donors other than 
HLA-identical siblings." New England Journal of Medicine 313: 765-771. 
Bellm, L. A., J. B. Epstein, et al. (2000). "Patient reports of complications of bone marrow 
transplantation." Support Care Cancer 8: 33-39. 
120 
 
Bolanos-Meade, J. (2006). "Update on the managment of acute graft-versus-host disease." 
Current Opinion in Oncology 18: 120-125. 
Brogdan, R. N. and D. McTravish (1992). "Budesonide. An updated review of its 
pharmacological properties and therapeutic effects in asthma and rhinitis." Drugs 44: 
375-407. 
Cahn, J. Y., J. P. Klein, et al. (2005). "Prospective evaluation of 2 acute graft-versus-host 
(GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie 
Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone 
Marrow Transplant Registry (IBMTR) prospective study." Blood 106: 1495-1500. 
Champlin, R., I. Khouri, et al. (2003). "Nonmyeloablative preparative regimens for allogeneic 
hematopoietic transplantation. Biology and current indications." Oncology (Huntingt) 
17(1): 94. 
Chor, A., A. Mello de Azevedo, et al. (2004). "Successful treatment of oral lesions of chronic 
lichenoid graft-vs.-host disease by the addition of low-level laser therapy to systemic 
immunosuppression." European Journal of Haematology 72: 222-224. 
Clarkson, A. (2003). Cochrane Database System Review. 
Comeau, T. B., J. B. Epstein, et al. (2001). "Taste and smell dysfunction in patients receiving 
chemotherapy: a review of current knowledge." Suport Care Cancer 9: 575-580. 
Confer, D. L. and J. P. Miller (2007). "Optimal donor selection: Beyond HLA." Biol Blood 
Marrow Transplant 13(Suppl 1): 83. 
Cooke, K. R., W. Krenger, et al. (1998). "Host reactive donor T cells are associated with lung 
injury after experimental allogeneic bone marrow transplantation." Blood 92: 2571-
2580. 
Copelan, E. A. (2006). "Medical Progress: Hematopoietic Stem-Cell Transplantation." The 
New England Journal of Medicine 354: 1813-1826. 
Coracin, F. L., M. E. Pizzigatti Correa, et al. (2006). "Major salivary gland damage in 
allogeneic hematopoietic progenitor cell transplantation assessed by scintigraphic 
methods." Bone Marrow Transplant 37: 955-959. 
Couriel, D. R., R. Saliba, et al. (2005). "Sirolimus in combination with tacrolimus and 
corticosteroids for the treatment of resistant chronic graft-versus-host disease." British 
Journal of Haematology 130: 409-417. 
Curtis, R. E., C. Metayer, et al. (2005). "Impact of chronic GVHD therapy on the development 
of squamous-cell cancers after hematopoietic stem-cell transplantation: an international 
case-control study." Blood 105: 3802-3811. 
Curtis, R. E., P. A. Rowlings, et al. (1997). "Solid cancers after bone marrow transplantation." 
New England Journal of Medicine 336: 897. 
121 
 
Cutler, C., J. H. Antin, et al. (2006). "Chronic graft-versus-host disease." Current Opinion in 
Oncology 18(2): 126-31. 
Cutler, C., S. Giri, et al. (2001). "Acute and chronic graft-versus-host disease after allogeneic 
peripheral-blood stem-cell and bone marrow transplantation: a meta analysis." Journal 
of Clinical Oncology 19: 3685-3691. 
da Fonseca, M. A., M. M. Schubert, et al. (1998). "Oral aspects and management of severe 
graft-vs-host disease in a young patient with beta-thalassemia: case report. ." Pediatric 
Dentistry 20: 57-61. 
DeLord, C., J. Treleaven, et al. (1999). "Vaginal stenosis following allogeneic bone marrow 
transplantation for acute myeloid leukaemia." Bone Marrow Transplant 23(523-525). 
Demarosi, F., G. Lodi, et al. (2005). "Oral malignancies following HSCT: graft-versus-host 
disease and other risk factors." Oral Oncology 41: 865-877. 
Donnelly, J. P., P. Muus, et al. (1992). "A scheme for daily monitoring of oral mucositis in 
allogeneic BMT recipients." Bone Marrow Transplant 9: 409-413. 
Duell, E. A., M. T. van Lint, et al. (1997). "Health and functional status of long-term survivors 
of bone marrow transplantation: EBMT Working Party on Late Effects and EULEP 
Study Group on Late Effects: European Group for Blood and Marrow Transplantation." 
Annals of Internal Medicine 126: 184-192. 
Dworkin, S. F. and L. LeResche (1992). "Research diagnostic criteria for temporomandibular 
disorders: Review, Criteria, Examinations and Specifications, Critique." Journal of 
Craniomandibular Disorders: Facial and Oral Pain 6(4): 301-355. 
Dyson, M., A. Agaiby, et al. (2002). "Photobiomodulation of human T-lymphocyte 
proliferation in vitro." Lasers Med Sci 17:A22 (abstract 61). 
Eckardt, A., O. Starke, et al. (2004). "Severe oral chronic graft-versus-host disease following 
allogeneic bone marrow transplantation: highly effective treatment with topical 
tacrolimus." Oral Oncology 40: 811-814. 
Eisen, D., C. N. Ellis, et al. (1990). "Effect of topical cyclosporine rinse on oral lichen planus." 
New England Journal of Medicine 323: 290-294. 
Elad, S., A. A. Garfunkel, et al. (1999). "Ultraviolet B irradiation: a new therapeutic concept for 
the management of oral manifestation of graft-versus-host disease." Oral Surgery, Oral 
Medicine, Oral Pathology, Oral Radiology and Endodontics 88(4): 444-450. 
Elad, S., R. Or, et al. (2003). "Budesonide: A novel treatment for oral chronic graft versus host 
disease." Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and 
Endodontics 95: 308-311. 
Elad, S., R. Or, et al. (2003). "CO2 laser in oral graft-versus-host disease: a pilot study." Bone 
Marrow Transplantation 32: 1031-1034. 
122 
 
Epstein, J. B., J. E. Raber-Drulacher, et al. (2009). "Advances in hematologic stem cell 
transplant: An update for oral health care providers." Oral Surgery, Oral Medicine, Oral 
Pathology, Oral Radiology, and Endodontics 107(3): 301-312. 
Epstein, J. B. and D. E. Reece (1994). "Topical cyclosporine A for treatment of oral chronic 
graft-versus-host disease." Bone Marrow Transplantation 13: 81-86. 
Epstein, J. B. and P. Stevenson-Moore (1992). "A clinical comparative trial of saliva substitutes 
in radiation-induced salivary gland hypofunction." Special Care in Dentistry 12(1): 21-
23. 
Epstein, J. B. and E. L. Truelove (1996). "Topical cyclosporine in a bioadhesive for treatment 
of oral lichenoid mucosal reactions: an open label clinical trial." Oral Surgery, Oral 
Medicine, Oral Pathology, Oral Radiology and Endodontics 82: 532-536. 
Ferrara, J. L., K. R. Cooke, et al. (2003). "The pathophysiology of acute graft-versus-host 
disease." Int J Hematol. 78: 181-187. 
Ferrara, J. L., R. Levy, et al. (1999). "Pathophysiologic mechanisms of acute graft-vs.-host 
disease." Biol Blood Marrow Transplant 5: 347-356. 
Ferrara, J. L. and P. Reddy (2006). "Pathophysiology of graft-versus-host disease." Seminars in 
Haematology 43: 3-10. 
Filipovich, A. H., D. Weisdorf, et al. (2005). "National Institute of Health Consensus 
Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host 
Disease. 1: Diagnosis and staging working group report." Biol Blood Marrow 
Transplant 11: 945-956. 
Fimiani, M., M. Di Renzo, et al. (2004). "Mechanism of action of extracorporeal 
photochemotherapy in chronic graft-versus-host disease." British Journal of 
Haematology 150: 1055-1060. 
Flomenberg, N., L. A. Baxter-Lowe, et al. (2004). "Impact of HLA class I and class II high-
resolution matching on outcomes of unrelated donor bone marrow transplantation: 
HLA-C mismatching is associated with a strong adverse effect on transplantation 
outcome." Blood 104(1923-1930). 
Fox, P. C. (2004). "Salivary enhancement therapies." Caries Research 38: 241-246. 
Franklin, R. M., K. R. Kenyon, et al. (1983). "Ocular manifestations of graft-versus-host 
disease." Ophthalmology 90(4-13). 
Giaccone, L., P. Martin, et al. (2005). "Safety and potential efficacy of low-dose methotrexate 
for treatment of chronic graft-versus-host disease." Bone Marrow Transplantation 36: 
337-341. 
Gilman, A., K. W. Chan, et al. (2000). "Hydroxychloroquine for the treatment of chronic graft-
versus-host disease." Biology of Blood and Marrow Transplantation 6: 327-324. 
123 
 
Goldman, J. M. (2002). "Treatment of chronic myeloid leukaemia: lessons and challenges." Int 
J Hematol. 76(Suppl 2): 189-192. 
Goldman, L. and D. Ausiello, Eds. (2007). Cecil Medicine. Philadelphia, Saunders Elsevier. 
Gratwahl, A., H. Baldomero, et al. (2002). "Current trends in hematopoietic stem cell 
transplantation in Europe." Blood 100: 2374-2386. 
Gratwohl, A., H. Baldomero, et al. (2007). "The EBMT activity survey 2006 on hematopoietic 
stem cell transplantation: focus on the use of cord blood products." Bone Marrow 
Transplant: 1-19. 
Hemidahl, A., G. Johnson, et al. (1985). "Oral condition of patients with leukaemia and severe 
aplastic anaemia. Follow-up 1 year after bone marrow transplantation " Oral Surgery, 
Oral Medicine, Oral Pathology, Oral Radiology and Endodontics 60: 498-504. 
Hewitt, A. and C. S. Farah (2007). "Bisphosphonate-related osteonecrosis of the jaws: a 
comprehensive review." Journal of Oral Pathology and Medicine: 1-10. 
Hill, G. and J. Ferrara (2000). "The primacy of the gastrointestinal tract as a target organ of 
acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic 
bone marrow transplantation." Blood 95(2754-2759). 
Ho, V. T. and R. J. Soiffer (2001). "The history and future of T-cell depletion as graft-versus-
host disease prophylaxis for allogeneic hematopoietic stem cell transplantation." Blood 
98: 3192. 
Hoffbrand, A. V., P. A. H. Moss, et al. (2006). Essential Haematology, Blackwell Publishing. 
Hoffman, R., E. J. Benz, et al. (2009). Hematology: Basic Principles and Practice, Churchill 
Livingstone Elsevier. 
Hugo, W. B. and A. R. Longworth (1964). "Some aspects of the mode of action of 
chlorhexidine." The Journal of Pharmacy and Pharmacology 16: 655-662. 
Imanguli, M. M., I. Alevizos, et al. (2008). "Oral graft-versus-host disease." Oral Diseases 14: 
396-412. 
Imanguli, M. M., S. Z. Pavletic, et al. (2006). "Chronic graft versus host disease of oral mucosa: 
Review of available therapies." Oral Surgery, Oral Medicine, Oral Pathology, Oral 
Radiology, and Endodontics 101(2): 175-183. 
Jacobsohn, D. A., B. Hewlett, et al. (2004). "Outcomes of unrelated cord blood transplants and 
allogeneic-related hematopoietic stem cell transplants in children with high-risk acute 
lymphocytic leukemia." Bone Marrow Transplant 34: 901-907. 
Jacobsohn, D. A. and G. B. Vogelsang (2002). "Novel pharmacotherapeutic approaches to 
prevention and treatment of GVHD." Drugs 62: 879-889. 
Jacobsohn, D. A. and G. B. Vogelsang (2007). "Acute graft versus host disease." Orphanet 
Journal of Rare Diseases 2(35): 1-9. 
124 
 
Janin-Mercier, A., A. Devergie, et al. (1984). "Immunohistologic and ultrastructural study of 
the sclerotic skin in chronic graft-versus-host disease in man." American Journal of 
Pathology 115: 296-306. 
Kahan, B. (2001). "Sirolimus: a comprehensive review." Expert Opinion in Pharmacotherapy 2: 
1903-1917. 
Khodls, A., D. Burr, et al. (2007). "Bisphosphonate-Associated Osteonecrosis of the Jaw: 
Report of a Task Force of the American Society for Bone and Mineral Research." 
Journal of Bone and Mineral Research 22(10): 1479-1491. 
Khosla, A., D. Burr, et al. (2007). "Bisphosphonate-Associated Osteonecrosis of the Jaw: 
Report of a Task Force of the American Society for Bone and Mineral Research." 
Journal of Bone and Mineral Research 22(10): 1479-1491. 
Lamey, P. J., F. T. Lundy, et al. (2004). "Sjogren's syndrome: a condition with features of 
chronic graft-versus-host disease: does duct cell adhesion or permeability play a role in 
pathogenesis?" Med Hypotheses 62: 825-829. 
Larsen, J., G. Nordstom, et al. (2007). "Factors associated with poor general health after stem 
cell transplantation." Suport Care Cancer 15: 849-857. 
Lee, S. J. (2005). "New approaches for preventing and treating chronic graft-versus-host 
disease." Blood 105: 4200-4206. 
Lee, S. J., J. P. Klein, et al. (2002). "Severity of chronic graft-versus-host disease: association 
with treatment-related mortality and relapse." Blood 100(2): 406-414. 
Levesque, J. P., F. Liu, et al. (2004). "Characterization of hematopoietic progenitor 
mobilization in protease-deficient mice." Blood 104: 65-72. 
Lindelof, B., B. Sigurgeirsson, et al. (1991). "PUVA and cancer: a large-scale epidemiological 
study." The Lancet 338: 91-93. 
Loprinzi, C. L., C. Ghosh, et al. (1997). "Phase III controlled evaluation of sucralfate to 
alleviate stomatitis in patients receiving fluorouracil-based chemotherapy." J Clinical 
Oncology 15: 1235-1238. 
Marinone, M. G., D. Rizzoni, et al. (1991). "Late taste disorders in bone marrow 
transplantation: clinical evaluation with taste solutions in autologous and allogeneic 
bone marrow recipients." Haematologica 76: 519-522. 
Marinone, M. G., D. Rizzoni, et al. (1991). "Late taste disorders in bone marrow 
transplantation: clinical evaluation with taste solutions in autologous and allogeneic 
bone marrow recipients." Haematologica 76: 519-522. 
Marx, R. E., Y. Sawatari, et al. (2005). "Bisphosphonate-induced exposed bone 
(osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and 
treatment." Journal of Oral Maxillofacial Surgery 63: 1567-1575. 
125 
 
Mathe, G., J. Bernard, et al. (1960). "New trials with homologous bone marrows grafts after 
total irradiation in children with acute leukemia in remission. The problem of the 
secondary syndrome in man." Revues Hematologique 15: 115-161. 
Meyers, J. D., N. Flournoy, et al. (1982). "Nonbacterial pneumonia after allogeneic marrow 
transplantation: a review of ten years‟ experience." Rev Infect Dis 4: 1119-32. 
Mielcarek, M., P. J. Martin, et al. (2003). "Graft-versus-host disease after nonmyeloablative 
versus conventional hematopoietic stem cell transplantation." Blood 102: 756-762. 
Miglorati, C. A., J. Casiglia, et al. (2005). "Managing the care of patients with bisphosphonate-
associatged osteonecrosis: An American Academy of Oral Medicine position paper." 
Journal of the American Dental Association 136: 1658-1668. 
Miller, J. S., Y. Soignier, et al. (2005). "Successful adoptive transfer and in vivo expansion of 
human haploidentical NK cells in patients with cancer." Blood 105. 
Nagler, R. M. and A. Nagler (1999). "Pilocarpine hydrochloride relieves xerostomia in chronic 
graft-versus-host disease: a sialometrical study." Bone Marrow Transplantation 23: 
1007-1011. 
Nakamura, S., A. Hiroki, et al. (1996). "Oral involvement in chronic graft-versus-host disease 
after allogeneic bone marrow transplantation." Oral Surgery Oral Medicine Oral 
Pathology Oral Radiology and Endodontics 82(556-563). 
Naylor, W. P., C. W. Douglass, et al. (1984). "The nonsurgical treatment of microstomia in 
scleroderma: A pilot study." Oral Surgery Oral Medicine Oral Pathology 57: 508-511. 
Nivison-Smith, I., K. F. Bradstock, et al. (2007). "Hematopoietic Stem Cell Transplantation in 
Australia and New Zealand, 1992-2004." Biol Blood Marrow Transplant 13: 905-912. 
Nivison-Smith, I., K. F. Bradstock, et al. (2005). "Haematopoietic stem cell transplantation in 
Australia and New Zealand, 1992-2001: progress report from the Australasian Bone 
Marrow Transplant Recipient Registry." Internal Medicine Journal 35: 18-27. 
Novince, C., B. B. Ward, et al. (2009). "Osteonecrosis of the Jaw: An Update and Review of 
Recommendations." Cells Tissues Organs 189: 275-283. 
Pavletic S. Z, Smith L.M, et al. (2005). "Prognostic factors of chronic graft-versus-host disease 
after allogenic blood stem-cell transplantation." American Journal of Hematology 
78(4): 265-274. 
Petersdorf, E., C. Anasetti, et al. (1998). "Effect of HLA matching on outcome of related and 
unrelated donor transplantation therapy for chronic myelogenous leukemia." 
Hematology Oncology Clinics of North America 12(1): 107-121. 
Posselt, U. (1962). Physiology of occlusion and rehabilitation. Oxford, Blackwell Scientific 
Publication. 
126 
 
Raber-Drulacher, J. E., J. B. Epstein, et al. (2002). "Periodontal infection in cancer patients 
treated with high-dose chemotherapy." Suport Care Cancer 10: 466-473. 
Ratanatharathorn, V., L. Ayash, et al. (2001). "Chronic graft-versus-host disease: clinical 
manifestation and therapy." Bone Marrow Transplantation 28: 121-129. 
Ritchie D, Seconi J, et al. (2005). "Prospective monitoring of tumour necrosis factor alpha and 
interferon gamma to predict the onset of acute and chronic graft-versus-host disease 
after allogenic stem cell transplantation." Biol Blood Marrow Transplant 105: 706-712. 
Ruescher, T. J., A. Sodeifi, et al. (1998). "The impact of mucositis on alpha-hemolytic 
streptococcal infection in patients undergoing autologous bone marrow transplantation 
for hematologic malignancies." Cancer 82: 2275-2281. 
Ruutu, T., J. Hermans, et al. (1998). "How should corticosteroids be used in the treatment of 
acute GVHD? EBMT Chronic Leukemia Working Party. European Group for Blood 
and Marrow Transplantation." Bone Marrow Transplant 22: 614. 
Ruutu, T., D. Niederwieser, et al. (1997). "A survey of the prophylaxis and treatment of acute 
GVHD in Europe: a report of the European Group for Blood and Marrow, 
Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT." Bone 
Marrow Transplant 19: 759-764. 
Saurat, J. H. (1981). "Cutaneous manifestations of graft-versus-host disease." International 
Journal Of Dermatology 20: 249-256. 
Schaffer, J. V. (2006). "The changing face of graft-verus-host disease." Seminars in Cutaneous 
Medicine and Surgery 25: 190-200. 
Schaffer, J. V., J. M. McNiff, et al. (2005). "Lichen sclerosis and eosinophilic fasiitis as 
manifestations of chronic graft-versus-host disease: expanding the sclerodermoid 
spectrum." Journal of the American Academy of Dermatology 53: 591-601. 
Schubert, M. M. and M. E. Correa (2008). "Oral Graft-Versus-Host Disease." The Dental 
Clinics of North America 52: 79-109. 
Schubert, M. M. and K. T. Izutsu (1987). "Iatrogenic causes of salivary gland dysfunction." 
Journal of Dental Research 66: 680-688. 
Schubert, M. M., K. M. Sullivan, et al. (1984). "Oral manifestations of chronic graft-versus-host 
disease." Arch Intern Medicine 144: 1591-1595. 
Schulte, C. M. and D. W. Beelen (2004). "Avascular Osteonecrosis After Allogeneic 
Hematopoietic Stem-Cell Transplantation: Diagnosis and Gender Matter." 
Transplantation 78: 1055-1063. 
Scully, C., S. Sonis, et al. (2006). "Oral mucositis." Oral Diseases 12: 229-241. 
Shlomchik, W. D. (2007). "Graft-versus-host disease." Nature Reviews-Immunology 7: 340-
352. 
127 
 
Shulman, H. M., D. Kleiner, et al. (2006). "Histopathologic diagnosis of chronic graft-versus-
host disease: National Institutes of Health Consensus Development Project on Criteria 
for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group 
Report." Biology of Blood and Marrow Transplantation 12(1): 31-47. 
Shulman, H. M., K. M. Sullivan, et al. (1980). "Chronic graft-versus-host syndrome in man: 
along term clinicopathologic study of 20 Seattle patients." American Journal of 
Medicine 69: 204-217. 
Soares, A. B., P. R. Faria, et al. (2005). "Chronic GVHD in minor salivary glands and oral 
mucosa: histopathological and immunohistochemical evaluation of 25 patients." Journal 
of Oral Pathology and Medicine 34: 368-373. 
Stem Cell Trialists' Collaborative Group (2005). "Stem Cell Trialists' Collaborative Group: 
Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in 
the management of hematological malignancies: an individual patient data meta-
analysis of nine randomized trials." Journal of Clinical Oncology 23: 5074-5087. 
Stewart, B. L., B. Storer, et al. (2004). "Duration of immunosuppresive treatment for chronic 
graft-versus-host disease." Blood 104: 3501-3506. 
Sullivan, K. M. (1986). "Acute and chronic graft-versus-host disease in man." International 
Journal of Cell Cloning 4: 42-93. 
Sullivan, K. M., E. Agura, et al. (1991). "Chronic graft-versus-host disease and other late 
complications of bone marrow transplantation." Semin Haematol 28: 250-259. 
Sullivan, K. M., P. L. Weiden, et al. (1981). "Chronic graft-versus-host disease in 52 patients: 
adverse natural course and successful treatment with combination immunosuppression." 
Blood 57: 267-276. 
Sutherland, H. J., G. M. Fyles, et al. (1997). "Quality of life after bone marrow transplantation: 
a comparison of patient reports with population norms." Bone Marrow Transplantation 
19: 1129-1136. 
Takahashi, s., T. Iseki, et al. (2004). "Single-institute comparative analysis of unrelated bone 
marrow transplantation and cord blood transplantation for adult patients with 
hematologic malignancies." Blood 104: 3813. 
Thomas, E. D., C. D. Buckner, et al. (1979). "Marrow transplantation for acute 
nonlymphoblastic leukaemia in first remission." New England Journal of Medicine 301: 
597. 
Thomas, E. D., C. D. Buckner, et al. (1979). "Marrow transplantation for acute 
nonlymphoblastic leukemia in first remission." New England Journal of Medicine 301: 
597. 
128 
 
Toubai, T., T. Sun, et al. (2008). "GVHD pathophysiology: is acute different from chronic?" 
Best Practice and Research Clinical Haematology 21(2): 101-117. 
Tran, T. D., K. Inui, et al. (2002). "Cerebral activation by the signals ascending through 
unmyelinated c-fibers in humans: a magnetoencephalographic study." Neuroscience 
113: 375–386. 
Treister, N. S., S. B. Woo, et al. (2005). "Oral chronic graft-versus-host disease in pediatric 
patients after hematopoietic stem cell transplantation." Biol Blood Marrow Transplant 
11: 721-731. 
Vela-Ojeda, J., M. A. Garcia-Ruiz, et al. (2004). "Allogeneic peripheral blood stem cell 
transplantation using reduced-intensity versus myeloablative conditioning regimens for 
the treatment of leukaemia." Stem Cells Devel 13: 571-578. 
Visch, L. L., E. J. Gravenmade, et al. (1986). "A double-blind crossover trial of CMC- and 
mucin- containing saliva substitutes." International Journal of Oral and Maxillofacial 
Surgery 15(4): 395-400. 
Vogelsang, G. B., D. Wolff, et al. (1996). "Treatment of chronic graft-versus-host disease with 
ultraviolet irradiation and psoralen (PUVA)." Bone Marrow Transplantation 17(6): 
1061-1067. 
Wackernagel, A., F. J. Legat, et al. (2007). "Psoralen plus UVA vs. UVB-311nm for the 
treatment of lichen planus." Photodermatology, Photoimmunology and Photomedicine 
23(1): 15-19. 
Wagner, J. E., J. N. Barker, et al. (2002). "Transplantation of unrelated donor umbilical cord 
blood in 102 patients with malignant and nonmalignant diseases: Influence of CD34 
cell dose and HLA disparity on treatment-related mortality and survival." Blood 100: 
1611. 
Wardley, A. M., G. C. Jayson, et al. (2000). "Prospective evaluation of oral mucositis in 
patients receiving myeloablative conditioning regimens and haemopoietic progenitor 
rescue." British Journal of Haematology 110: 292-299. 
Weng, H. R. and Schouenborg (1996). "Nociceptive inhibition of withdrawal reflex responses 
increases over time in spinalized rats." Journal of Neuroreport 7: 1310–1314. 
Wolff, D., V. Anders, et al. (2004). "Oral PUVA and topical steroids for treatment of oral 
manifesatation of chronic graft-vs-host disease." Photodermatology, Photoimmunology 
and Photomedicine 20(4): 184-190. 
Woo, S. B., A. J. Lee, et al. (1997). "Graft-vs-Host Disease." Critical Reviews in Oral Biology 
and Medicine 8(2): 201-216. 
129 
 
Wood, P. and S. J. Proctor (1990). "The potential use of thalidomide in the therapy of graft-
versus-host disease- a review of clinical and laboratory information." Leukaemia 
Research 14: 395-399. 
www.clinicaltrials.gov (2009). Effectiveness of Topical Thalidomide to Treat Chronic Graft-
Versus-Host Disease Related Stomatitis. 
Yoo, E., A. H. Rook, et al. (1996). "Apoptosis induction of ultraviolet light A and 
photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of 
therapeutic action." Journal of Investigative Dermatology 107: 235-242. 
Zarychanski, R., E. Elphee, et al. (2006). "Osteonecrosis of the jaw associated with pamidronate 
therapy." American Journal of Hematology 81(73-75). 
 
 
  
130 
 
 
 
